



Nester's
Microbiology

A HUMAN PERSPECTIVE

Denise Anderson | Sarah Salm | Mira Beins

Denise G. Anderson

UNIVERSITY OF WASHINGTON

Sarah N. Salm

BOROUGH OF MANHATTAN
COMMUNITY COLLEGE

Mira Beins

UNIVERSITY OF WASHINGTON

Eugene W. Nester

UNIVERSITY OF WASHINGTON

**Mc
Graw
Hill**

Tenth Edition



NESTER'S MICROBIOLOGY: A HUMAN PERSPECTIVE, TENTH EDITION

Published by McGraw Hill LLC, 1325 Avenue of the Americas, New York, NY 10121. Copyright © 2022 by McGraw Hill LLC. All rights reserved. Printed in the United States of America. Previous editions © 2019, 2016, and 2012. No part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written consent of McGraw Hill LLC, including, but not limited to, in any network or other electronic storage or transmission, or broadcast for distance learning.

Some ancillaries, including electronic and print components, may not be available to customers outside the United States.

This book is printed on acid-free paper.

1 2 3 4 5 6 7 8 9 LWI 23 22 21

ISBN 978-1-260-73550-5 (bound edition)
MHID 1-260-73550-8 (bound edition)
ISBN 978-1-264-34198-6 (loose-leaf edition)
MHID 1-264-34198-9 (loose-leaf edition)

Portfolio Manager: *Lauren Vondra*
Product Developer: *Erin DeHeck*
Marketing Manager: *Tami Hodge*
Content Project Managers: *Laura Bies / Rachael Hillebrand*
Senior Buyer: *Laura Fuller*
Lead Designer: *David Hash*
Content Licensing Specialist: *Beth Cray*
Cover Image: ©National Institute of Allergy and Infectious Diseases (NIAID)
Compositor: *MPS Limited*


All credits appearing on page or at the end of the book are considered to be an extension of the copyright page.

Library of Congress Cataloging-in-Publication Data

Names: Anderson, Denise G. (Denise Gayle), author. | Salm, Sarah, author. | Beins, Mira, author. | Allen, Deborah (Deborah Patricia), author.
Title: Nester's microbiology : a human perspective / Denise G. Anderson, Sarah N. Salm, Mira Beins, [Deborah Allen].
Other titles: Microbiology
Description: Tenth edition. | New York, NY : McGraw Hill Education, [2022] | Includes index.
Identifiers: LCCN 2020041282 | ISBN 9781260735505 (hardcover; alk. paper)
Subjects: MESH: Microbiological Phenomena | Microbiological Techniques | Communicable Diseases—microbiology
Classification: LCC QR41.2 | NLM QW 4 | DDC 579—dc23
LC record available at <https://lccn.loc.gov/2020041282>

The Internet addresses listed in the text were accurate at the time of publication. The inclusion of a website does not indicate an endorsement by the authors or McGraw Hill LLC, and McGraw Hill LLC does not guarantee the accuracy of the information presented at these sites.

mheducation.com/highered





Brief Contents

PART I

Life and Death of Microorganisms

1. Humans and the Microbial World 1
2. The Molecules of Life 20
3. Cells and Methods to Observe Them 44
4. Dynamics of Microbial Growth 90
5. Control of Microbial Growth 117
6. Microbial Metabolism: Fueling Cell Growth 137
7. The Blueprint of Life, from DNA to Protein 175
8. Bacterial Genetics 203
9. Biotechnology 232

PART II

The Microbial World

10. Identifying and Classifying Microorganisms 255
11. The Diversity of Bacteria and Archaea 274
12. The Eukaryotic Members of the Microbial World 305
13. Viruses, Viroids, and Prions 329

PART III

Microorganisms and Humans

14. The Innate Immune Response 360
15. The Adaptive Immune Response 385
16. Host-Microbe Interactions 415
17. Applications of Immune Responses 439
18. Immunological Disorders 464
19. Epidemiology 481
20. Antimicrobial Medications 504

PART IV

Infectious Diseases

21. Respiratory System Infections 536
22. Skin Infections 582
23. Wound Infections 609
24. Digestive System Infections 630
25. Blood and Lymphatic Infections 672
26. Nervous System Infections 703
27. Genitourinary Tract Infections 738

PART V

Applied Microbiology

28. Microbial Ecology 777
29. Environmental Microbiology: Treatment of Water, Wastes, and Polluted Habitats 796
30. Food Microbiology 810

APPENDICES A-1

GLOSSARY/INDEX GI-1

About the Authors

The Nester Team:

Different Perspectives, One Vision, One Voice

The authors of this edition may be a set of individuals with different insights and unique experiences, but their cooperative relationship defines the word “team.” What drives them is a single shared goal: to create the most learning-friendly introductory microbiology textbook available. Each chapter was edited with students in mind, using simpler words where appropriate while maintaining the scientific rigor so important for today’s healthcare professionals.



Richard Moore

Denise Anderson

Denise Anderson is a Senior Lecturer Emeritus in the Department of Microbiology at the University of Washington, where she taught a variety of courses including general microbiology, medical bacteriology laboratory, recombinant DNA techniques, and medical mycology/parasitology laboratory for over 30 years. Equipped with a diverse educational background, including

undergraduate work in nutrition and graduate work in food science and in microbiology, she first discovered a passion for teaching when she taught microbiology laboratory courses as part of her graduate training. Her enthusiastic teaching style, fueled by regular doses of Seattle’s famous coffee, received high reviews from her students.

Denise now relaxes in the Yorkshire Dales of England, where she lives with her husband, Richard Moore. When not editing textbook chapters, she can usually be found walking scenic footpaths, chatting with friends, fighting weeds in her garden, or enjoying a fermented beverage at the local pub.



Sandy Coetzee

Sarah Salm

Sarah Salm is a Professor at the Borough of Manhattan Community College (BMCC) of the City University of New York, where she teaches microbiology, anatomy and physiology, and general biology. She earned her undergraduate and doctoral degrees at the University of the Witwatersrand in Johannesburg, South Africa.

She later moved to New York, where she did postdoctoral work at the NYU School of Medicine. Her research background is diverse and includes plant virology, prostate cancer, and bacteria in contaminated water sources.



Mira Beins

Mira Beins

Mira Beins is an Associate Teaching Professor in the Department of Microbiology at the University of Washington, where she teaches general microbiology, medical bacteriology, and medical mycology/parasitology. She completed her undergraduate studies in Molecular Biology and Biotechnology at the University of the Philippines before moving

to Wisconsin for graduate work in Microbiology. Her graduate and postdoctoral research both focused on virology, which solidified her belief that viruses are amazing—although she now begrudgingly admits that bacteria, fungi, and eukaryotic parasites are pretty cool, too.

Mira lives in Seattle with her husband Mike and two kids, Maya and Noah. When she’s not busy teaching or driving the kids to their many activities, she enjoys reading books, watching movies, hanging out with friends and family, and planning the next family trip (which Denise hopes will be to the Yorkshire Dales!).




Mike Bohrer

Deborah Allen

Deborah Allen is a Professor at Jefferson College in Missouri, where she teaches microbiology as well as several other courses for students entering allied health careers. Her graduate work was in zoology at the University of Oklahoma and in neurobiology and behavior at Cornell University.

She participated in cancer research at the University of Arkansas Medical Center before embarking on a career in publishing, working in acquisitions and development for books in the life sciences. She is now thrilled to be working on the other end of the desk with the Nester team. Away from campus, Deborah reads or listens to her favorite Eve Dallas novels, floats the rivers and listens to folk music in the Ozarks, and fully appreciates the local microbes while visiting Missouri wineries.



Courtesy Eugene Nester

Eugene Nester

Gene (Eugene) Nester was instrumental in establishing the text’s reputation for excellence over the decades. Although no longer an active member of the author team, he wrote the original version of the present text with Evans Roberts and Nancy Pearsall more than 30 years ago. That text, *Microbiology: Molecules, Microbes and Man*, pioneered the organ system approach to the study of infectious disease

and was developed specifically for allied health sciences.

Presentation Tools Allow Instructors to Customize Lecture

Everything you need, in one location

Enhanced Lecture Presentations contain lecture outlines, art, photos, tables, and animations embedded where appropriate. Fully customizable, but complete and ready to use, these presentations will enable you to spend less time preparing for lecture!

Animations—More than 100 animations bring key concepts to life; available for instructors and students.

Accessible PPTs—Our lecture presentations are formatted per the latest accessibility guidelines. Alternative text, written by our textbook author team, is included for all images and static tables.


Take your course online—*easily*—with one-click Digital Lecture Capture

McGraw-Hill Tegrity[®] records and distributes your lecture with just a click of a button. Students can view them anytime/anywhere via computer, tablet, or mobile device. Tegrity Campus indexes as it records your slideshow presentations and anything shown on your computer so **students can use keywords to find exactly what they want to study.**


Remote Proctoring & Browser-Locking Capabilities

New remote proctoring and browser-locking capabilities, hosted by Proctorio within Connect, provide control of the assessment environment by enabling security options and verifying the identity of the student.


Seamlessly integrated within Connect, these services allow instructors to control students' assessment experience by restricting browser activity, recording students' activity, and verifying students are doing their own work.



Source: Janice Haney Carr/CDC



Instant and detailed reporting gives instructors an at-a-glance view of potential academic integrity concerns, thereby avoiding personal bias and supporting evidence-based claims.




Instructors: Student Success Starts with You

Tools to enhance your unique voice

Want to build your own course? No problem. Prefer to use our turnkey, prebuilt course? Easy. Want to make changes throughout the semester? Sure. And you'll save time with Connect's auto-grading too.

65%
Less Time
Grading



Laptop: McGraw Hill; Woman/dog: George Doyle/Getty Images

Study made personal

Incorporate adaptive study resources like SmartBook® 2.0 into your course and help your students be better prepared in less time. Learn more about the powerful personalized learning experience available in SmartBook 2.0 at www.mheducation.com/highered/connect/smartbook

Affordable solutions, added value



Make technology work for you with LMS integration for single sign-on access, mobile access to the digital textbook, and reports to quickly show you how each of your students is doing. And with our Inclusive Access program you can provide all these tools at a discount to your students. Ask your McGraw Hill representative for more information.

Padlock: Jobalou/Getty Images

Solutions for your challenges



A product isn't a solution. Real solutions are affordable, reliable, and come with training and ongoing support when you need it and how you want it. Visit www.supportateverystep.com for videos and resources both you and your students can use throughout the semester.

Checkmark: Jobalou/Getty Images

SUPPORT AT
every step

Students: Get Learning that Fits You

Effective tools for efficient studying


Connect is designed to make you more productive with simple, flexible, intuitive tools that maximize your study time and meet your individual learning needs. Get learning that works for you with Connect.

Study anytime, anywhere

Download the free ReadAnywhere app and access your online eBook or SmartBook 2.0 assignments when it's convenient, even if you're offline. And since the app automatically syncs with your eBook and SmartBook 2.0 assignments in Connect, all of your work is available every time you open it. Find out more at www.mheducation.com/readanywhere

"I really liked this app—it made it easy to study when you don't have your textbook in front of you."

- Jordan Cunningham,
Eastern Washington University



Calendar: owattaphotos/Getty Images

Everything you need in one place

Your Connect course has everything you need—whether reading on your digital eBook or completing assignments for class, Connect makes it easy to get your work done.

Learning for everyone

McGraw Hill works directly with Accessibility Services Departments and faculty to meet the learning needs of all students. Please contact your Accessibility Services Office and ask them to email accessibility@mheducation.com, or visit www.mheducation.com/about/accessibility for more information.

Top: Jenner Images/Getty Images, Left: Hero Images/Getty Images, Right: Hero Images/Getty Images



FOCUS ON UNDERSTANDING . . .

Student-Friendly Illustrations

Introduce the “big picture”

Focus figures provide an overview or highlight a key concept.

Keep the big picture in focus

A highlighted mini-version of the overview figure is often incorporated into the upper left corner of subsequent figures, helping students see how those figures fit into the big picture.




FIGURE 15.10




FIGURE 15.13




FIGURE 15.14




FIGURE 15.16




FIGURE 15.1 Overview of the Adaptive Immune Response Cell-mediated immunity protects against antigens within host cells (intracellular antigens); humoral immunity protects against antigens in blood and tissue fluid (extracellular antigens). In this diagram, solid arrows represent the path of a cell or molecule; dashed arrows represent a cell's interactions and effector functions; antigen receptors and memory cells are not shown.

How does cell-mediated immunity eliminate intracellular antigens?

is responsible for that recognition (figure 15.2). The antigen receptors on a single lymphocyte are identical and therefore recognize the same antigen, but because the body has hundreds of millions of different lymphocytes, the immune system can recognize a nearly infinite assortment of antigens. Conventional T-cell receptors (TCRs) only bind an antigen “presented” by one of the body’s own cells, an interaction guided by a surface molecule called a CD marker (CD stands for cluster of differentiation to reflect that scientists use the molecules to distinguish different groups of cells). Cytotoxic T cells have a CD marker called CD8, which is why the cells are sometimes referred to as CD8 T cells or CD8+ T cells; in contrast, helper T cells have a CD marker called CD4, which is why the cells are sometimes referred to as CD4 T cells or CD4+ T cells. B-cell receptors (BCRs) are essentially

membrane-anchored versions of the Y-shaped antibody molecules that the B cell is programmed to make. Unlike T-cell receptors, they bind free antigens (in other words, antigens not presented by one of the body’s own cells). The two arms of the BCR are identical to each other, resulting in two antigen-binding sites. Cell-mediated and humoral immunity are both powerful and, if misdirected, can damage the body’s own tissues. To provide the immune tolerance necessary to prevent inappropriate responses, two sequential processes are used: Central tolerance. This takes place as lymphocytes mature (T cells in the thymus marrow and B cells in the bone marrow); it eliminates immature T and B cells found to recognize certain “self” molecules.

“Provides a logical unfolding conceptual framework that fosters better understanding.”

—Jamal Bittar, University of Toledo





FIGURE 15.18

Walk through the processes

Step-by-step figures direct the student using numbered icons, often with corresponding icons in the text.

“The text and illustrations are ‘tight’ and give each other good support.”

—Richard Shipee, Vincennes University



Introduce the body systems

Each disease chapter includes a stunning figure that introduces the students to the anatomy of the body system.

Distribution of the Pathogen

Infections are often described according to the distribution of the causative agent in the body. In a **localized infection**, the microbe is limited to a small area; an example is a boil caused by *Staphylococcus aureus*. In a **systemic infection**, the infectious agent disseminates (spreads) throughout the body; an example is Lyme disease. Systemic infections often include a characteristic set of signs and symptoms—such as fever, fatigue, and headache—that result from the systemic immune response to the infecting agent.

The suffix *-emia* means “in the blood.” Thus, **bacteremia** indicates that bacteria are circulating in the bloodstream. Note that this term does not necessarily imply a disease state. A person can become bacteremic for a short period of time after forceful tooth brushing. On the other hand, infection-induced bacteremia can lead to a life-threatening systemic inflammatory response, a condition called **sepsis**. **Toxemia** indicates that toxins are circulating in the bloodstream. The organism that causes tetanus, for instance, produces a localized infection, yet its toxins circulate in the bloodstream. The term **viremia** indicates that viral particles are circulating in the bloodstream.

MicroAssessment 16.3

A primary pathogen can cause disease in an otherwise healthy individual; an opportunist causes disease in an immunocompromised host. The course of infectious disease includes an incubation period, illness, and a period of convalescence. Infections can be acute, chronic, or latent; they can be localized or systemic.

- Why are diseases caused by opportunists becoming more frequent?
- Give an example of a microbe that causes a latent infection.
- What factors might contribute to a long incubation period?

16.4 ■ Determining the Cause of an Infectious Disease

Learning Outcome

- List Koch’s postulates, and compare them to the molecular Koch’s postulates.

Criteria are needed to guide scientists as they try to determine the cause of an infectious disease. They can also be helpful when studying the disease process.

Koch’s Postulates

The steps that Robert Koch used to show that *Bacillus anthracis* causes anthrax (see **A Glimpse of History**) are now known as **Koch’s postulates**. Although they were never meant to be applied rigidly, they still provide scientists with a logical framework for establishing that a given microbe causes a certain infectious disease (**figure 16.3**):





FIGURE 16.3 Koch’s Postulates These criteria provide a foundation for establishing that a given microbe causes a specific disease.

To fulfill Koch’s postulates, why must an organism suspected of causing the disease be able to grow in laboratory medium?

- The microorganism is present in every case of the disease.
- The microorganism must be grown in pure culture from diseased hosts.
- The same disease can be produced when a pure culture of the microorganism is introduced into susceptible hosts.
- The microorganism must be recovered from the experimentally infected hosts.

Encourage deeper understanding

Figures have accompanying questions that encourage students to think more carefully about the concept illustrated in a figure.



FOCUS ON UNDERSTANDING . . .

Student-Friendly Chapter Features

Provide the tools for understanding

Key Terms for each chapter are defined on the opening page.

Share the history

A **Glimpse of History** opens each chapter, featuring engaging stories about the men and women who pioneered the field of microbiology.

Define the expectations

Learning outcomes are found at the beginning of each numbered section, allowing organization, evaluation, and assessment of instruction.

Assess understanding


A **MicroAssessment** at the end of each numbered section summarizes the concepts and includes review questions, usually featuring one that stimulates critical thinking (indicated by a light bulb icon).

Engage the reader

MicroBytes found throughout the chapter provide small “bytes” of information, capturing the reader’s attention.

26

Nervous System Infections



Structure of West Nile virus particles. ©Science Picture Co/Getty Images

A Glimpse of History

Today it is hard to appreciate the fear and loathing once attached to leprosy (*lepro*, meaning “scaly”). Many historical and religious texts refer to several disfiguring skin diseases, including leprosy, and portray those suffering from the diseases as unclean and sinful. Lepers were regularly segregated from mainstream society.

Gerhard Henrik Armauer Hansen (1841–1912) was a Norwegian physician with many interests, ranging from science to religion to polar exploration. After graduating from medical school, he went to work with Dr. Daniel C. Danielson, a leading authority on leprosy. Danielson believed that leprosy was a hereditary disease and considered the idea that it was contagious to be a “peasant superstition.” Hansen, however, disproved Danielson’s hypothesis in careful studies conducted over a number of years. He found a unique bacterium associated with the disease in every leprosy patient he studied. His 1873 report of the findings marked the first time that a specific bacterium was linked to a disease—almost a decade before Koch’s proof of the cause of tuberculosis.

In the United States, even during the first half of the twentieth century, people diagnosed with leprosy risked having their houses burned to destroy the source of infection. Their names were changed to avoid embarrassing their families, and they were sent to a leprosarium such as the one at Carville, Louisiana, which was surrounded by a 12-foot fence topped with barbed wire. Sufferers were separated from spouses and children and were denied the right to marry or vote. Those who tried to escape were captured and brought back in handcuffs. The Carville leprosarium was finally closed and converted to a military-style academy in 1999.

KEY TERMS

Blood-Brain Barrier (BBB) Cells that function together to create a protective semipermeable border that separates the CNS from the bloodstream.

Central Nervous System (CNS) Brain and spinal cord.

Cerebrospinal Fluid (CSF) Fluid produced in the brain that flows within and around the CNS.

Encephalitis Inflammation of the brain.

Meninges Membranes covering the brain and spinal cord.

Meningitis Inflammation of the meninges.

Peripheral Nervous System (PNS) Division of the nervous system that carries information to and from the CNS.

Transmissible Spongiform Encephalopathy (TSE) Chronic degenerative brain disease caused by prions; characterized by spongy appearance of brain tissue.

Because the word *leprosy* carries centuries of grim overtones, many people prefer to use the term *Hansen’s disease*, a name that honors the discoverer of the causative bacterium. Today, the disease can be treated.

Nervous system infections are frightening. They threaten a person’s ability to move, feel, or even think. Consider poliomyelitis, which can result in a paralyzed limb or the inability to breathe without mechanical assistance. Hansen’s disease (leprosy) can result in loss of fingers or toes or deformity of the face. Infections of the brain or its covering membranes can render a child deaf or intellectually disabled. Before the discovery of antibiotics, bacterial infections of the nervous system were often fatal. Fortunately, these infections are uncommon.

26.1 ■ Anatomy, Physiology, and Ecology of the Nervous System

Learning Outcomes

1. Describe how information flows through and between neurons.
2. Differentiate between the central nervous system and the peripheral nervous system.
3. Explain how bone, cerebrospinal fluid, meninges, and the blood-brain barrier protect the central nervous system.

Nerve cells work together, transmitting electrical impulses throughout the body like a highly sophisticated circuit board. Each nerve cell, or **neuron**, has three functionally distinct regions: (1) branching projections called dendrites, (2) the cell

703

MicroAssessment 3.2

Peptidoglycan is a molecule unique to bacteria that provides strength to the cell wall. The Gram-positive cell wall is composed of a relatively thick layer of peptidoglycan as well as teichoic acids. Gram-negative cell walls have a thin layer of peptidoglycan and a lipopolysaccharide-containing outer membrane. Penicillin and lysozyme interfere with the structural integrity of peptidoglycan. *Mycoplasma* species lack a cell wall. Archaea have a variety of cell wall types.

4. What is the significance of lipid A?
5. How does the action of penicillin differ from that of lysozyme?
6. Explain why penicillin kills only actively multiplying cells, whereas lysozyme kills cells in any stage of growth. 💡

MicroByte

There are more bacteria in just one person’s mouth than there are people in the world!

Highlight the relevance

Focus on a Case boxes describe realistic clinical, veterinary, or environmental situations, along with questions and discussions designed to highlight the relevance of the information.

Provide perspective

Focus Your Perspective boxes show how microorganisms and their products influence our lives in many different ways.

Introduce the concepts

Focus on a Disease boxes introduce a general category of disease (pneumonia, diarrheal disease, meningitis, sexually transmitted infections), giving students a framework for understanding specific diseases.

Inspire the learner

Focus on the Future boxes describe pending challenges facing current and future microbiologists.

- **Summary** briefly reviews the key points.
- **Short Answer** questions review major chapter concepts.
- **Multiple Choice** questions allow self-testing; answers are provided in Appendix IV.
- **Application** questions provide an opportunity to use knowledge of microbiology to solve real-world problems.
- **Critical Thinking** questions encourage practice in analysis and problem solving that can be used by the student in any subject.

Build the story

Logical chapter order helps students understand and connect the concepts.

FOCUS ON A CASE 14.1

A 9-year-old boy with cystic fibrosis—a genetic disease that causes a number of problems, including the buildup of thick, sticky mucus in the lungs—complained of feeling tired, out of breath, and always coughing. When his mother took him to the doctor, she mentioned that his cough was productive, meaning that it contained sputum (pronounced *spew-num*). She was particularly concerned that the sputum was a blue-green color. His doctor immediately suspected a lung infection by *Pseudomonas aeruginosa*—a common complication of cystic fibrosis. A sputum sample was collected and sent to the clinical laboratory.

In the clinical laboratory, the sample was plated onto MacConkey agar and blood agar and incubated. Mucoid colonies surrounded by a bluish-green color grew on both types of agar media. The colonies on MacConkey had no pink coloration, so the medical technologist concluded that the cells did not ferment lactose. She noted the blue-green color on the

The patient was treated with antibiotics, with only limited success. Like most cystic fibrosis patients, he developed a chronic lung infection that continued to require repeated treatment.

1. What role did cystic fibrosis play in the disease process?
2. What is the significance of the mucoid phenotype of the colonies?
3. How would the siderophore the iron-binding compound benefit the bacterium?
4. Why would the boy's lung infection make his pre-existing respiratory problems even worse?

Discussion

1. Cystic fibrosis patients often have an accumulation of thick mucus in their lungs, which interferes with the mucociliary escalator and other first-line defenses. With a compromised (weakened) mucociliary escalator,

aeruginosa cells to form biofilms. The biofilm protects the bacterial cells from various components of the immune system, including antimicrobial peptides and phagocytes. Bacteria growing within a biofilm are much more difficult for the immune system to destroy.

3. Siderophores help the bacterium obtain iron from the host. Recall that the body produces iron-binding proteins, including lactoferrin and transferrin; this prevents microbes from using the host's iron and thereby limits their growth. Microorganisms that make siderophores essentially engage in a "tug-of-war" with the body over iron. This tug-of-war is especially important for *P. aeruginosa* because iron levels influence biofilm formation. When iron is limiting, *P. aeruginosa* cells are motile and do not initiate biofilm formation.
4. In response to a bacterial infection in the lungs, an inflammatory response develops. Inflammation involves the release of signaling molecules that cause blood vessels to dilate, allowing more blood to flow to the area. This increases the number of white blood cells in the area, releasing their

FOCUS YOUR PERSPECTIVE 9.1

The COVID-19 Response—The Power of Biotechnology

The COVID-19 response serves as an excellent illustration of the power of biotechnology. Because of several of the technologies described in this chapter, the pandemic's global outcome—although devastating—resulted in fewer deaths than many feared or predicted.

SARS-CoV-2, the virus that causes COVID-19, has an RNA genome. If a researcher needs a DNA copy of that genome, the enzyme reverse transcriptase is used to make cDNA. When the virus was first discovered in China, a cDNA copy of its genome was cloned and then sequenced. That sequence was then shared with scientists around the world, initiating what became a global effort to control the disease.

A researcher needs a DNA copy of that genome, the enzyme reverse transcriptase is used to make cDNA. When the virus was first discovered in China, a cDNA copy of its genome was cloned and then sequenced. That sequence was then shared with scientists around the world, initiating what became a global effort to control the disease.

technologies; not only do CRISPR-Cas-based tests give results in about an hour or less, they do not compete with PCR-based tests with respect to the required reagents. The first CRISPR-Cas-based diagnostic test was approved for use only in certified laboratories, but researchers also worked toward developing similar but instrument-free versions that can be completed on-site (comparable to home pregnancy tests).

Data obtained via high-throughput sequencing were used to track the global spread of SARS-CoV-2. The tracking methods rely on detecting spontaneous mutations that inevitably occur as the virus replicates; these mutations serve as

facilitated research aimed at developing targeted antiviral therapies, as described in Focus on the Future 20.1. By analyzing the viral genome, scientists determined the amino acid sequence of key proteins essential for replication of the virus. Relatively soon thereafter, the 3-dimensional structure of two of those proteins was determined—one that the virus uses to attach to and then enter host cells and one it uses to replicate its genome. Knowing those protein structures allows scientists to focus their efforts on developing compounds that specifically target the parts essential for the structure's function—for example, the exact site on the attachment protein that contacts a host cell. The structures of other SARS-CoV-2

FOCUS ON PNEUMONIA

Pneumonia is a disease of the lower respiratory tract caused by bacterial, viral, or fungal infection of the lungs. An inflammatory response to the infection generally results in the alveoli (air sacs) of the lungs filling with fluids such as pus and blood. Pneumonia is the leading cause of death due to infectious disease in the United States.

Signs and Symptoms

The signs and symptoms of pneumonia generally include cough, chills, shortness of breath, fever, and chest pain. In severe cases, the patient may develop cyanosis (bluish skin color) due to poor blood oxygenation. Pneumonia ranges from mild to life-threatening, depending largely on the causative agent but also on any underlying health problems of the patient. It is often accompanied by a productive cough, meaning that a pus- and mucus-containing fluid called **sputum** comes up from the lungs. Some pathogens cause what are referred to as atypical pneu-

destroy invading microbes cannot effectively eliminate the pathogen initially. Once opsonizing antibodies are produced during a B-cell response, however, phagocytes can remove the microbes.

The damage from pneumonia is largely a result of the inflammatory response. As the capillaries become leaky during inflammation, fluids collect in the alveoli and interfere with O₂ and CO₂ exchange. In addition, phagocytes and other leukocytes are recruited to the site of infection, and mucus production increases. Accumulating leukocytes and mucus create a thick substance that may clog the alveoli, a condition called consolidation. Consolidation is most common in severe bacterial pneumonia. The inflammatory response seen in severe pneumonia often affects nerve endings in the pleura, causing pain.

Epidemiology

Pneumonias are often categorized as either community-acquired, meaning that they develop in members of the general public, or

FOCUS ON THE FUTURE 20.1

The Race to Develop COVID-19 Treatments


Almost immediately after the emergence of the disease now called COVID-19, scientists raced to find effective treatments. An early focus was on drug repurposing—the use of approved or investigational drugs for new therapeutic uses. Approved drugs are those that have undergone the testing required for the U.S. Food and Drug Administration (FDA) to authorize marketing of the drug; investigational drugs are experimental drugs that the FDA has authorized for testing in humans. The repurposing options considered for COVID-19 treatments included not just antiviral drugs, but also medications to control the infection-induced cytokine storm and other damaging immune responses. An enormous advantage of a repurposed drug is that it has already gone through clinical trials so

so scientists from around the globe rushed to identify the functions and 3-dimensional structures of various SARS-CoV-2 proteins (the process was aided by earlier studies of the related virus, SARS-CoV). Armed with that information, other scientists then worked towards designing small molecules that specifically block a given protein's function. The virus can potentially mutate to develop resistance to a single medication, however, so a variety of drugs, each interfering with a different target, will likely be required. The SARS-CoV-2-specific medications are still early in the development stages at the time of this writing, but their targets are in some of the same categories as those of other antiviral medications:

its interaction with other viral proteins, various inhibitors that target the viral replication machinery are being developed. Some are nucleoside and nucleotide analogs, but finding effective versions of those is complicated by the fact that the replicase of SARS-CoV-2 has proofreading ability, which is unusual among RNA viruses. Thus, if the SARS-CoV-2 replicase incorporates an analog during RNA synthesis, the proofreading function might recognize and remove that analog, thereby avoiding production of a defective RNA molecule. Another potential SARS-CoV-2 target is a protein complex that adds a 5' cap to viral RNA to make it

Review the information

End-of-chapter review encourages students to revisit the information.



FOCUS ON UNDERSTANDING . . .

Student-Friendly Descriptions

Include analogies

WHY? Analogies provide students a comfortable framework for making sense of difficult topics. Here's an example from chapter 14.

Innate Immunity *The innate immune system has three general components: first-line defenses, sensor systems, and innate effector actions. As a useful analogy, think of the defense systems of a high-security building or compound: The first-line defenses are the security walls surrounding the property; the sensor systems are the security cameras scattered throughout the property, monitoring the environment for signs of invasion; and the effector actions are the security teams sent to remove any invaders that have been detected, thereby eliminating the threat (figure 14.1a).*



Steve Cole/E+/Getty Images



© Image Source, all rights reserved.





Moodboard/Brand X Pictures/Getty Images

Emphasize the logic

WHY? Descriptions that emphasize the logic of processes make it easier for students to understand and retain the information. Here's an example from chapter 6.

TABLE 6.2 Precursor Metabolites		
Precursor Metabolite	Biosynthetic Role	Pathway (or Step) Generated
Glucose-6-phosphate	Lipopolysaccharide	Glycolysis
Fructose-6-phosphate	Peptidoglycan	Glycolysis
Dihydroxyacetone phosphate	Lipids (glycerol component)	Glycolysis
3-Phosphoglycerate	Proteins (the amino acids cysteine, glycine, and serine)	Glycolysis
Phosphoenolpyruvate	Proteins (the amino acids phenylalanine, tryptophan, and tyrosine)	Glycolysis
Pyruvate	Proteins (the amino acids alanine, leucine, and valine)	Glycolysis
Ribose-5-phosphate	Nucleic acids and proteins (the amino acid histidine)	Pentose phosphate cycle
Erythrose-4-phosphate	Proteins (the amino acids phenylalanine, tryptophan, and tyrosine)	Pentose phosphate cycle
Acetyl-CoA	Lipids (fatty acids)	Transition step
α -Ketoglutarate	Proteins (the amino acids arginine, glutamate, glutamine, and proline)	TCA cycle
Oxaloacetate	Proteins (the amino acids aspartate, asparagine, isoleucine, lysine, methionine, and threonine)	TCA cycle


Note: The colored icons in the table are used in figures throughout the chapter to represent the respective precursor metabolites.



Introduce the players *Certain intermediates of catabolic pathways can be used in anabolic pathways; therefore they link these two types of pathways. These intermediates—precursor metabolites—serve as carbon skeletons from which subunits of macromolecules can be made (table 6.2).*

Reinforce the concept *A cell's metabolic pathways make it easy for that cell to use glucose for multiple purposes. Think of the cells as extensive biological recycling centers that routinely process millions of glucose molecules (figure 6.9). Molecules that remain on the central deconstruction line are oxidized completely to CO₂, releasing the maximum amount of energy. Some breakdown intermediates, however, can exit that line to be used in biosynthesis.*

Put the pieces together *Three key metabolic pathways—the central metabolic pathways—gradually oxidize glucose to CO₂, as described by the following general reaction (figure 6.10):*



The pathways are catabolic, but the precursor metabolites and reducing power they generate can also be diverted for use in biosynthesis.

Student-Friendly Disease Presentations

Help students think like experts

Within each body system chapter, diseases are separated by major taxonomic category (bacteria, viruses, fungi, protozoa). This organization reflects a major consideration with respect to treatment options, an important consideration for students going into healthcare-related fields.

Part IV Infectious Diseases 693

Causative Agent
Zika virus (ZIKV) is an enveloped, single-stranded RNA arbovirus in the family *Flaviviridae*, and it is transmitted by *Aedes* mosquitoes.

Pathogenesis
Studies indicate that when Zika virus enters the host, it binds to a receptor found on a number of different human tissues, which helps to explain the potential involvement of the skin, joints, nerves, and eyes. Unlike other flaviviruses, ZIKV has been detected in the fluid surrounding a fetus as well as in its brain—regions that are typically immunologically privileged, meaning that they are isolated from destructive immune mechanisms (see Focus Your Perspective 18.1).

Microcephaly is a recognized consequence of congenital Zika virus infection, but since the 2015 outbreak in Brazil, researchers found that the damage is more extensive than previously thought. Because of this, the outcome of in utero infection is now referred to as congenital Zika syndrome. ZIKV preferentially infects neural cells in the fetus, and in particular, neural stem cells from which the brain develops; these cells are present throughout fetal development, so infection during any trimester of pregnancy can damage the brain. Even newborns with normal head size can rapidly exhibit developmental delays and neurological abnormalities.

Epidemiology
ZIKV is transmitted by the bite of infected *Aedes* mosquitoes. Most cases involve *A. aegypti*, a species that feeds primarily on people and survives best in warm climates. *A. albopictus* probably transmits the disease less often because it feeds on various animals and therefore is less likely to bite people. It is a concern, however, because it tolerates cooler climates and thereby has a wider geographic range. In fact, its distribution has expanded as the mosquito has inadvertently been introduced to countries around the globe.

ZIKV is also sexually transmitted. ZIKV RNA has been detected in blood, semen, saliva, and secretions of the female genital tract, as well as in other body fluids. Females should avoid getting pregnant for at least 8 weeks after possible exposure. Males should avoid unprotected sex for 6 months after exposure, as the virus can be found in the semen for that long after infection. In 2016, the CDC established the U.S. Zika Pregnancy Registry to monitor infections and to provide recommendations and services for women who are concerned about infection during pregnancy.

Treatment and Prevention
No specific treatment is used for Zika virus infection. Aspirin and non-steroidal pain relievers should be avoided until the possibility of infection with dengue fever virus has been eliminated because it could worsen the hemorrhaging associated with that disease. No approved vaccine for Zika virus disease is currently available, but because of the devastating effect of ZIKV on a developing fetus, significant efforts have been made towards developing one. Although several are in clinical trials, completing those is now challenging because the number of ZIKV infections has dropped dramatically since 2017, thereby making it difficult to determine a vaccine's effectiveness. The best preventive measures are avoiding mosquito bites and controlling the mosquito vector. Long sleeves and pants along with the use of mosquito nets will help people to avoid bites. Sources of standing water where mosquitoes can breed should be eliminated, both inside and outside. As with dengue, the use of *Wolbachia* to control mosquito populations is a promising approach. Dengue fever, chikungunya, and Zika virus disease are compared in table 25.12.

	Dengue and Severe Dengue	Chikungunya	Zika Virus Disease
Signs and Symptoms	Often asymptomatic; fever, headache, rash, and severe joint pain; in severe dengue, bleeding and shock can occur, as well as disseminated intravascular coagulation (DIC).	Similar to dengue fever, but followed by severe joint pain that may become chronic.	Usually asymptomatic; mild disease with fever, rash, joint pain, red eyes, rare nervous system involvement; congenital Zika syndrome.
Incubation Period	Usually 4 to 7 days	Usually 3 to 7 days	2 to 14 days
Causative Agents	Dengue virus serotypes DENV1, DENV2, DENV3, and DENV4; single-stranded RNA virus	Chikungunya virus; single-stranded RNA virus	Zika virus; single-stranded RNA virus
Pathogenesis	Pro-inflammatory cytokines cause leaky blood vessels, dehydration, and hemorrhaging; in severe dengue, DIC and shock may be fatal.	Release of cytokines that affect immune cells; bone destruction.	Virus binds to receptors on a variety of cells; enters fluid around fetus and brain; affects neural stem cells.
Epidemiology	Mosquito-borne; found predominantly in tropical and subtropical regions, but range is increasing. Severe dengue usually occurs in children under 15 years old.	Mosquito-borne; mainly in Africa and Asia, but now in Europe and the Americas.	Mosquito-borne and sexually transmitted; females should avoid pregnancy for 8 weeks after exposure; males should use condoms for 6 months.
Treatment and Prevention	Treatment: analgesics for pain; oral rehydration therapy and blood or platelet transfusions if bleeding occurs. Prevention: vector control; vaccine in limited areas.	Treatment: analgesics for pain and oral rehydration. Prevention: vector control.	Treatment: no specific treatment. Prevention: vector control.

Summarize each disease's characteristics


Summary tables serve as brief reminders of the important features of each disease. Major diseases are represented with an enhanced summary table that includes an outline of the disease process keyed to a human figure, showing the entry and exit of the pathogen.

Review the diseases as a group

Each disease chapter ends with a table that summarizes the key features of the diseases discussed in that chapter.

25 Blood and Lymphatic Infections 672

A Glimpse of History 672
Key Terms 672



Steve Gschmeissner/Science Photo Library/Alamy Stock Photo

25.1 Anatomy, Physiology, and Ecology of the Blood and Lymphatic Systems 673

The Heart 673
Blood Vessels 673
Lymphatics (Lymphatic Vessels) 673
Spleen 674

25.2 Bacterial Diseases of the Blood and Lymphatic Systems 674

Infective Endocarditis 674
Sepsis and Septic Shock 675
Plague ("Black Death") 676
Lyme Disease 678
Vibrio vulnificus Infection 682
Tularemia ("Rabbit Fever" or "Deer Fly Fever") 683
Brucellosis ("Undulant Fever" or "Bang's Disease") 684

25.3 Viral Diseases of the Blood and Lymphatic Systems 686

Infectious Mononucleosis ("Mono" or "Kissing Disease") 686
Ebola Disease (EBOV) and Marburg Disease (MARD) 688
Yellow Fever 689
Dengue and Severe Dengue 690
Chikungunya 691
Zika Virus Disease 692

25.4 Protozoan Diseases of the Blood and Lymphatic Systems 694

Malaria 694

FOCUS ON A CASE 25.1 692

DISEASES IN REVIEW 25.1: Blood and Lymphatic Infections 699

SUMMARY 700

REVIEW QUESTIONS 701

Provide a consistent conceptual framework

Disease discussions are separated into consistent subsections, providing a conceptual framework and breaking the material into "bite-sized" pieces.

Diseases in Review 21.1

Respiratory System Diseases

Disease	Causative Agent	Comment	Summary Table
BACTERIAL INFECTIONS OF THE UPPER RESPIRATORY TRACT			
Conjunctivitis (pink eye), otitis media (earache), sinus infection	Usually <i>Haemophilus influenzae</i> or <i>Streptococcus pneumoniae</i>	Often occur together; factors involved in the transmission are unknown.	
Streptococcal pharyngitis ("strep throat")	<i>Streptococcus pyogenes</i> (group A streptococcus)	Treated with antibiotics, partly to avoid sequelae; must be distinguished from viral pharyngitis, which cannot be treated with antibiotics.	Table 21.3
Diphtheria	<i>Corynebacterium diphtheriae</i>	Toxin-mediated disease characterized by pseudomembrane in the upper respiratory tract. Preventable by vaccination.	Table 21.4
VIRAL INFECTIONS OF THE UPPER RESPIRATORY TRACT			
Common cold	Rhinoviruses and other viruses	Runny nose, sore throat, and cough are due to the inflammatory response and cell destruction.	Table 21.5
Adenovirus pharyngitis	Adenoviruses	Similar to the common cold but with fever; spread to the lower respiratory tract can result in severe disease.	Table 21.6
BACTERIAL INFECTIONS OF THE LOWER RESPIRATORY TRACT			
Pneumococcal pneumonia	<i>Streptococcus pneumoniae</i>	Organism common in the throat of healthy people; causes disease when mucociliary escalator is impaired or with underlying conditions. Vaccine that protects against multiple strains is available.	Table 21.7
Klebsiella pneumonia	<i>Klebsiella</i> species, commonly <i>K. pneumoniae</i>	Common hospital-acquired bacterium, characterized by thick, bloody, jelly-like sputum. Drug resistance is a major problem.	Table 21.7
Mycoplasma pneumonia ("walking pneumonia")	<i>Mycoplasma pneumoniae</i>	Relatively mild pneumonia; common among college students and military recruits. Cannot be treated with medications that inhibit cell wall synthesis.	Table 21.7
Pertussis ("whooping cough")	<i>Bordetella pertussis</i>	Characterized by frequent violent coughing. Preventable by vaccination.	Table 21.8
Tuberculosis ("TB")	<i>Mycobacterium tuberculosis</i>	Most infections result in latent tuberculosis infection (LTBI), but these can reactivate to cause tuberculosis disease (TB disease). Treated using combination drug therapy, but drug resistance is an increasing problem.	Table 21.9
Legionnaires' disease	<i>Legionella pneumophila</i>	Transmitted via aerosolized water droplets; smokers and those with impaired defenses are most at risk of developing disease.	Table 21.10
Inhalation anthrax	<i>Bacillus anthracis</i>	Rare zoonotic disease; may be associated with bioterrorism; high case-fatality rate.	Table 21.11
VIRAL INFECTIONS OF THE LOWER RESPIRATORY TRACT			
Influenza ("flu")	Influenza viruses	New vaccine developed yearly; viruses change seasonally due to antigenic drift; antigenic shifts cause pandemics.	Table 21.12
Respiratory syncytial virus infections	RSV	Serious disease in infants, young children, and the elderly.	Table 21.13
COVID-19, SARS and MERS	Coronaviruses	Emerging infectious diseases characterized by severe lower respiratory symptoms; zoonotic.	Table 21.14
Hantavirus pulmonary syndrome	Hantaviruses	Acquired via inhaled dust contaminated with rodent saliva, urine, or feces. Frequently fatal.	Table 21.15
FUNGAL INFECTIONS OF THE RESPIRATORY TRACT			
Coccidioidomycosis ("valley fever")	<i>Coccidioides immitis</i> and <i>C. posadasii</i>	Environmental reservoir (soil in semi-arid desert areas); most infections are asymptomatic.	Table 21.16
Histoplasmosis ("spelunker's disease")	<i>Histoplasma capsulatum</i>	Environmental reservoir (bat droppings and soil enriched with bird droppings); most infections are asymptomatic.	Table 21.17
Pneumocystis pneumonia (PCP)	<i>Pneumocystis jirovecii</i> (formerly carinii)	Organism is an opportunistic fungus that causes serious lung disease in immunocompromised people, such as those with HIV/AIDS.	Table 21.18

UPDATES—Maintaining the Cutting Edge

Global Changes

- Added information about COVID-19 and SARS-CoV-2, including the following boxes:
 - Focus Your Perspective 9.1 (*The COVID-19 Response—The Power of Biotechnology*)
 - Focus on a Case 13.1
 - Focus on the Future 20.1 (*The Race to Develop COVID-19 Treatments*)
 - Focus Your Perspective 21.1 (*A Global Lesson in Microbiology: The COVID-19 Pandemic*)
- Updated disease statistics, vaccine recommendations, treatments, and terminology
- Rearranged some content to improve flow in the digital text (the information most relevant to a particular figure is now in the paragraph immediately preceding the figure, and summary tables have been moved to the end of the coverage)
- Converted many of the descriptions that support multi-step figures to bullet lists that correspond to the steps
- Continued “wordsmithing” to improve the clarity and readability of the descriptions

Key Changes in Individual Chapters

Chapter 1 – Humans and the Microbial World

- Added SARS-CoV-2 and *Candida auris* to the section on emerging pathogens
- Added the African swine fever to the list of epidemics in non-human populations
- Expanded the coverage of the human microbiome
- Defined the term *strain*
- Moved the information about bacterial cell shape from chapter 3 to section 1.3
- Added a MicroByte about the Microbiome Conservancy collecting/storing fecal samples from populations around the world

Chapter 2 – The Molecules of Life

- Consolidated and expanded the information on water’s characteristics
- Added a subsection on short-chain fatty acids, to allow a description of butyrate

- Added a description of waxes
- Described the distinction between a Lewis symbol and a Lewis structure
- Rearranged the three-part figure showing DNA
- Added a MicroByte on the use of artificial intelligence and a video game to determine protein folding

Chapter 3 – Cells and Methods to Observe Them

- Rearranged the chapter sections so that cell structure and function is discussed before microscopy and staining methods; revised the chapter title to reflect the change
- Revised the coverage of active transport systems to place more emphasis on the concept rather than the different types
- Updated the section on gas vesicles to include information about other protein-based compartments (bacterial microcompartments and encapsulin nanocompartments)
- Introduced the term *archaellum*
- Described periplasm in Gram-positive cells
- Moved the information about bacterial cell shape to chapter 1

Chapter 4 – Dynamics of Microbial Growth

- Introduced the term *contact-dependent growth inhibition*

Chapter 5 – Control of Microbial Growth

- Combined the physical methods of microbial control into one section
- Expanded the discussion of biosafety levels
- Added the recent FDA rulings that limit the use of many previously allowed ingredients in antiseptic lotions until they are shown to be safe and effective

Chapter 6 – Microbial Metabolism: Fueling Cell Growth

- Rearranged the information about energy sources and terminal electron acceptors so that the more conceptually simple information comes first.
- Revised tables 6.2 (Precursor Metabolites) and 6.4 (Some Vitamins and Their Use in Coenzymes)
- Added new figure (6.11) to emphasize the difference in energy yield between aerobic respiration and fermentation

- Simplified the detailed discussion of the central metabolic pathways
- Simplified the discussion of photosynthesis

Chapter 7 – The Blueprint of Life, from DNA to Protein

- Combined the subsections that describe DNA replication
- Added a MicroByte about the target of the new influenza medication (baloxavir marboxil)
- Added a MicroByte about the first approved RNAi-based medication
- Split the figure that illustrates the process of translation to emphasize its three phases (initiation, elongation, and termination; now figures 7.5–7.17)

Chapter 8 – Bacterial Genetics

- Changed the term *silent mutation* to *synonymous mutation*, and explained that this type of mutation is not always silent
- Changed the term *DNA-mediated transformation* to *bacterial transformation*
- Broadened the coverage of section 8.10 (now “Genome Variability”) and added the term *pan-genome*
- Simplified the format of the end-of-chapter multiple choice questions

Chapter 9 – Biotechnology

- Added a new Focus Your Perspective Box: *The COVID-19 Response—The Power of Biotechnology*
- Emphasized the importance of CRISPR-Cas technologies by creating a numbered section (section 9.3); the expanded coverage includes a description of a rapid COVID-19 diagnostic test that relies on the technologies
- Expanded the chapter introduction to emphasize the applications of biotechnology
- Added a MicroByte about a bacterial enzyme engineered to efficiently break down a common type of plastic
- Changed the title of section 9.2 to “Molecular Cloning” (was “Genetic Engineering”) to reflect a more narrow focus
- Added a simplified view of the cloning process (in a bullet list format) that matches figure 9.4
- Converted the description of vectors to a bullet list that matches figure 9.6 (was 9.8)
- Converted the description of how a PCR product is generated to a bullet list that matches figure 9.13 (was 9.17)
- Deleted the section on the dideoxy chain termination method of DNA sequencing
- Updated the Focus On the Future box by changing the name of the initiative described to *All of Us*

Chapter 10 – Identifying and Classifying Microorganisms

- Updated information about the new online *Bergey’s Manual of Systematics of Archaea and Bacteria*
- Changed the example of nomenclature change to *Cutibacterium acnes*

Chapter 11 – The Diversity of Bacteria and Archaea

- Added information about the release of *Wolbachia*-infected mosquitoes as a means to prevent mosquito-borne diseases

Chapter 12 – The Eukaryotic Members of the Microbial World

- Extensive revision, including new photographs throughout; moved the section on protozoa forward, and increased the medical emphasis throughout
- Expanded the discussion of the difficulties of classification
- Added a disease-based grouping of fungi
- Added information about the spread of a fungal disease that destroys banana plants
- Expanded the discussion of medically important protozoa
- Added a figure that illustrates the origin of chloroplasts through primary endosymbiosis
- Simplified the figure that illustrates phylogenetic groups of eukaryotes (now figure 12.18)

Chapter 13 – Viruses, Viroids, and Prions

- Changed the topic of the Focus on a Case box to COVID-19
- Updated viral taxonomy
- Added *Pneumoviridae* to table 13.1
- Bulleted the steps of the lytic bacteriophage life cycle to match figure 13.5
- Bulleted the steps of specialized transduction to match figure 13.9
- Split the figure showing replication strategies of animal viruses into three separate figures for clarity (now figures 13.12–13.14)
- Updated information on viruses and human tumors to include oncogenic and oncolytic viruses
- Added Focus on the Future 13.1: *The Potential of Phage Therapy*

Chapter 14 – The Innate Immune Response

- Modified and updated the descriptions of granulocytes, particularly neutrophils

- Expanded the information on cell types to increase the emphasis on mast cells
- Updated the information on macrophages to indicate that tissue-resident macrophages can self-renew
- Separated the description of inflammation into vascular changes and cellular changes
- Expanded the discussion on damaging effects of inflammation
- Added necroptosis to the paragraph that describes pyroptosis

Chapter 15 – The Adaptive Immune Response

- Extensive revision; reorganized the chapter to create a more linear flow (T cells and their activation are now described before B cells)
- Expanded and rearranged the overview to reflect the new chapter organization
- Expanded the discussion of immune tolerance to distinguish between central tolerance and peripheral tolerance

Chapter 16 – Host-Microbe Interactions

- Increased the emphasis on the importance of butyrate on intestinal barrier functions
- Revised the discussion of Koch’s postulates

Chapter 17 – Applications of Immune Responses

- Moved the chapter forward (was chapter 18) so that monoclonal antibodies could be described before the chapter that mentions their use in allergy therapies.
- Added a section on immunotherapies (section 17.3), particularly focusing on the new cancer therapies (check-point inhibitors and CAR T cells)
- Added the new the dengue disease vaccine to table 17.5
- Added information about the new combination vaccine that includes HepB

Chapter 18 – Immunological Disorders

- Bulleted the steps involved in type I hypersensitivities to match the accompanying figure
- Updated information on type II hypersensitivities
- Updated the information on immune disorder treatments, including adding information on immunotherapy
- Eliminated the section on treatment of autoimmune diseases, and instead describe the treatments in the context of the respective conditions
- Added a MicroByte on the Neurological Conditions Surveillance System (NNCSS)

Chapter 19 – Epidemiology

- Added COVID-19 as an example of the significance of asymptomatic infections in the spread of a disease
- Changed the MicroByte in section 19.1 to mention the secondary attack rate of measles
- Added measles to the factors that contribute to disease emergence
- Updated table of notifiable infectious diseases
- Updated the description of the *Morbidity and Mortality Weekly Report*
- Added the URL for the CDC’s National Notifiable Diseases Surveillance System (NNDS)
- Added COVID-19 and *Candida auris* infection to the section on emerging diseases

Chapter 20 – Antimicrobial Medications

- Added a Focus on the Future Box: *The Race to Develop COVID-19 Treatments*
- Explained that oral administration of poorly absorbed medications is useful for treating intestinal infections
- Added information about the new rifamycin for treating some types of travelers’ diarrhea
- Updated the section on *Mycobacterium tuberculosis* resistance by adding information about the new combination treatment specifically for XDR-TB
- Updated the table that describes the microorganisms on the CDC’s list of antibiotic resistance threats (table 20.2)
- Mentioned the resistance of *Candida auris* in the section on antifungal medications
- Updated the section on antiviral medications by adding a subsection on cap-snatching inhibitors
- Added moxidectin for treating river blindness and triclabendazole for treating liver flukes to table 20.5

Chapter 21 – Respiratory System Infections

- Added a Focus Your Perspective Box: *A Global Lesson in Microbiology: The COVID-19 Pandemic*
- Expanded the discussion of coronavirus lower respiratory tract infections to include not only SARS and MERS, but also COVID-19
- Updated the information on Group A *Streptococcus* virulence factors to include only those clearly associated with pathogenesis
- Updated the discussion of mycoplasmal pneumonia pathogenesis to include the CARDS toxin, which has been shown to be a key virulence factor
- Changed Legionellosis to Legionnaires’ disease to more specifically refer to *Legionella pneumonia*

- Bulleted the discussion of TB pathogenesis to match figure 21.19
- Updated the discussion on the WHO's program to combat TB; also introduced the newly FDA-approved drug trial program for XDR-TB called Nix-TB
- Updated the pathogenesis discussion on several viral diseases, including the common cold, adenovirus respiratory infections, hantavirus pulmonary syndrome
- Updated the classification of influenza viruses to include influenza D; updated the influenza strain nomenclature to be more in line with the CDC and WHO; introduced the new anti-influenza medication baloxavir
- Updated the information on RSV classification, pathogenesis, and treatment

Chapter 22 – Skin Infections

- Added new bullet list of characteristic skin lesions and rashes, including descriptions and disease examples
- Expanded the section on acne
- Added disease summary tables for acne and hair follicle infections
- Expanded the information on impetigo
- Added information about hand-foot-and-mouth disease (HFMD)

Chapter 23 – Wound Infections

- Added a new part to figure 23.9 to illustrate the mechanism of tetanospasmin
- Reduced the coverage of streptobacillary rat bite fever, assigning it to a new section called *Other Bacterial Bite Wound Infections*

Chapter 24 – Digestive System Infections

- Added a MicroByte on the Global Microbiome Conservancy to section 24.1
- Updated the information on dental caries and modified the accompanying figure
- Updated Focus on a Case 24.1 to reflect diagnosis of *H. pylori* infections by the urea breath test
- Changed the heading *Typhoid and Paratyphoid Fevers* to *Enteric Fever (Typhoid and Paratyphoid)*

Chapter 25 – Blood and Lymphatic Infections

- Revised the section on sepsis and simplified the accompanying figure

- Updated the information on different forms of tularemia
- Updated and explained the evolving terminology of Ebola disease and Marburg disease
- Updated the terminology by changing *dengue fever* to *dengue* and *severe dengue*
- Added a description of how *Wolbachia*-infected mosquitoes can be used to control dengue and other mosquito-borne diseases

Chapter 26 – Nervous System Infections

- Changed the heading “Viral Encephalitis” to “West Nile and Other Types of Viral Encephalitis,” and put the focus on West Nile encephalitis
- Changed the MicroByte topic in section 26.3 to acute flaccid myelitis (AFM)
- Updated the information on African trypanosomiasis (African sleeping sickness)

Chapter 27 – Genitourinary Tract Infections

- Updated the coverage of leptospirosis
- Updated Focus Your Perspective 27.1 and changed the title to “Conquering Syphilis”
- Added information about a new monoclonal antibody approved for use as a component of antiretroviral therapy (ART)
- Updated the information on HIV disease
- Removed tables 27.16 (People at Increased Risk for HIV Disease) and 27.18 (Behaviors that Help Control an AIDS Epidemic)

Chapter 28 – Microbial Ecology

- Added the definition of oligotroph
- Revised the section on mycorrhiza; added the terms *arbuscular mycorrhiza* and *Hartig net*, as well as information about fungal networks
- Add a MicroByte to section 28.6 about corn that produces syrup-coated aerial roots to nourish nitrogen-fixing bacteria

Chapter 29 – Environmental Microbiology: Treatment of Water, Wastes, and Polluted Habitats

- Expanded the description of MUG/ONPG

Chapter 30 – Food Microbiology

- Bulleted the descriptions that support figures 30.4 and 30.5



Acknowledgments

First and foremost, special thanks goes to Gene Nester, the leader of the team that wrote the first version of what became *Microbiology, A Human Perspective*. His efforts helped pioneer a new type of introductory microbiology textbook, designed specifically for students entering healthcare-related fields. This edition proudly builds on that original vision.

We would also like to thank the reviewers and other instructors who guided us as we developed this edition, as well as those whose input has helped the text evolve over the years. Deciding what to eliminate, what to add, and what to rearrange is always difficult, so we appreciate your suggestions.

Past students have been incredibly helpful as well. Every question helps us decide which parts of the textbook need more clarification, and every compliment lets us know when we're on the right track.

Special thanks also go to our friends, families, and colleagues for picking up the many hairs we tore out while working on the textbook. Revising a textbook is an all-consuming task—from the initial development stage to proofing the pages during production—and numerous people have acted as advisors and cheerleaders throughout. This text would not exist without the contributions of our strong group of supporters.

A list of acknowledgments is not complete without thanking our fearless leaders and friends from McGraw-Hill. Our product developer Erin DeHeck and portfolio manager Lauren Vondra not only gave inspiration and sound advice, but they also laughed at our jokes and barely rolled their eyes at our idiosyncrasies. Lauren Vondra and Tami Hodge helped ensure that word got out about this new edition, allowing it to find its way into your hands. It was wonderful to have Laura Bies as our content project manager to guide us through some rocky waters on the way to publication. Additionally, we would like to thank digital content project manager Rachael Hillebrand for helping produce our digital resources that support the text and Lisa Burgess, who provided many wonderful photographs.

We hope that this text will be interesting and educational for students and helpful to instructors. Our goal is excellence, so with that in mind we would appreciate any comments and suggestions from our readers.

*Denise Anderson
Sarah Salm
Mira Beins*

Reviewers for the Tenth Edition

Andrea R. Beyer, *Virginia State University*
Bruce Bleakley, *South Dakota State University*
Anar A. Brahmhatt, *San Diego Mesa College*
Linda D. Bruslind, *Oregon State University*
Carron Bryant, *East Mississippi Community College*
Matthew B. Crook, *Weber State University*
Jeremiah Davie, *D'Youville College*
Karim Dawkins, *Broward College*
Matthew Dodge, *Olympic College*
Robert A. Holmes, *University of Missouri–Kansas City*
Joshua Hughes, *Dakota State University*
Ilko B. Iliev, *Southern University at Shreveport*
Karen Kowalski, *Tidewater Community College*
Ruhul Kuddus, *Utah Valley University*
Lorie Lana, *Stevenson University*
Eddystone C. Nebel, *Delgado Community College*
Olabisi Ojo, *Albany State University*
Jennifer L. B. Roshek, *Stevenson University*
Dan Smith, *Seattle University*
Renato V. Tameta, *Schenectady County Community College*
Krystal Taylor, *Beaufort County Community College*
Roger Wainwright, *University of Central Arkansas*

Contents

About the Authors iv

PART I

Life and Death of Microorganisms

1 Humans and the Microbial World 1

A Glimpse of History 1

Key Terms 1

1.1 The Dispute over Spontaneous Generation 2

- Early Experiments 2
- Experiments of Pasteur 2
- Experiments of Tyndall 2
- The Golden Age of Microbiology 3
- The Scientific Method 3

1.2 Microbiology: A Human Perspective 5

- The Human Microbiome 5
- Microorganisms in the Environment 6
- Commercial Benefits of Microorganisms 6
- Microbes as Research Tools 7
- Microbes and Disease 7

1.3 Members of the Microbial World 10

- Scientific Names 11
- Bacteria 13
- Archaea 14
- Eukarya 14
- Acellular Infectious Agents 15

FOCUS ON A CASE 1.1 9

FOCUS YOUR PERSPECTIVE 1.1: Every Rule Has an Exception 12

FOCUS ON THE FUTURE 1.1: Meet the Microbiomes! 17

SUMMARY 17

REVIEW QUESTIONS 18

2 The Molecules of Life 20

A Glimpse of History 20

Key Terms 20

2.1 Elements and Atoms 21

- Atomic Structure 21
- The Role of Electrons 21
- Isotopes 22

2.2 Chemical Bonds and Reactions 23

- Ions and Ionic Bonds 23

- Covalent Bonds 23
- Hydrogen Bonds 24
- Molarity 24
- Chemical Reactions 25

2.3 Water, pH, and Buffers 26

- Water 26
- pH of Aqueous Solutions 27
- Buffers 27

2.4 Organic Molecules 28

- Carbohydrates 29
- Lipids 30
- Proteins 33
- Nucleic Acids 38

FOCUS ON A CASE 2.1 32

FOCUS YOUR PERSPECTIVE 2.1: Right-Handed and Left-Handed Molecules 36

SUMMARY 41

REVIEW QUESTIONS 42

3 Cells and Methods to Observe Them 44

A Glimpse of History 44

Key Terms 44


PROKARYOTIC CELL STRUCTURES AND THEIR FUNCTIONS

3.1 The Cytoplasmic Membrane of Prokaryotic Cells 46


- Structure of the Cytoplasmic Membrane 46
- Permeability of the Cytoplasmic Membrane 46
- The Role of the Cytoplasmic Membrane in Energy Transformation 47
- Transport of Small Molecules Across the Cytoplasmic Membrane 48
- Protein Secretion 49

3.2 The Cell Wall of Prokaryotic Cells 50


- Peptidoglycan 50
- The Gram-Positive Cell Wall 50
- The Gram-Negative Cell Wall 52
- Antibacterial Substances That Target Peptidoglycan 54
- Bacteria That Lack a Cell Wall 54
- Cell Walls of Archaea 55



INTERFOTO/Alamy, Stock Photo



Steve Gschmeissner/Getty Images



Lisa Burgess/McGraw-Hill Education

3.3 Structures Outside the Cell Wall of Prokaryotic Cells 56

- Capsules and Slime Layers 56
- Flagella 56
- Pili 58

3.4 Internal Components of Prokaryotic Cells 59

- Chromosome and Plasmids 59
- Ribosomes 59
- Cytoskeleton 60
- Storage Granules 60
- Protein-Based Compartments 60
- Endospores 60

EUKARYOTIC CELL STRUCTURES AND THEIR FUNCTIONS**3.5 Cytoplasmic Membrane of Eukaryotic Cells 64**

- Structure and Function of the Cytoplasmic Membrane 64
- Transfer of Molecules Across the Cytoplasmic Membrane 64

3.6 Protein Structures Within Eukaryotic Cells 66

- Ribosomes 66
- Cytoskeleton 66
- Flagella and Cilia 67

3.7 Membrane-Bound Organelles of Eukaryotic Cells 68

- Nucleus 68
- Mitochondria 68
- Chloroplasts 70
- Endoplasmic Reticulum (ER) 70
- Golgi Apparatus 71
- Lysosomes and Peroxisomes 71

METHODS TO OBSERVE CELLS**3.8 Microscopes 72**

- Principles of Light Microscopy:
 - Bright-Field Microscopes 73
- Light Microscopes That Increase Contrast 74
- Light Microscopes That Detect Fluorescence 76
- Electron Microscopes 77
- Scanning Probe Microscopes 78

3.9 Preparing Specimens for Light Microscopy 81

- Simple Staining 81
- Differential Staining 82
- Special Stains to Observe Cell Structures 84
- Fluorescent Dyes and Tags 85

FOCUS ON A CASE 3.1 55**FOCUS YOUR PERSPECTIVE 3.1: Pathogens Hijacking Actin 67**

SUMMARY 86

REVIEW QUESTIONS 88

4 Dynamics of Microbial Growth 90**A Glimpse of History 90****Key Terms 90****4.1 Principles of Microbial Growth 90****4.2 Microbial Growth in Nature 91**

- Biofilms 92
- Interactions of Mixed Microbial Communities 93

4.3 Microbial Growth in Laboratory Conditions 93

- Obtaining a Pure Culture 94
- The Growth Curve 95
- Colony Growth 96
- Continuous Culture 96

4.4 Environmental Factors That Influence Microbial Growth 97

- Temperature Requirements 97
- Oxygen (O₂) Requirements 98
- pH 99
- Water Availability 99

4.5 Nutritional Factors That Influence Microbial Growth 100

- Required Elements 100
- Growth Factors 101
- Energy Sources 101
- Nutritional Diversity 101

4.6 Cultivating Microorganisms in the Laboratory 103

- General Categories of Culture Media 103
- Special Types of Culture Media 104
- Providing Appropriate Atmospheric Conditions 105
- Enrichment Cultures 106


4.7 Methods to Detect and Measure Microbial Growth 107

- Direct Cell Counts 107
- Viable Cell Counts 108
- Measuring Biomass 110
- Detecting Cell Products 112


FOCUS ON A CASE 4.1 102**FOCUS YOUR PERSPECTIVE 4.1: Can Microorganisms Live on Only Rocks and Water? 103****FOCUS ON THE FUTURE 4.1: Seeing How the Other 99% Lives 113**

SUMMARY 114

REVIEW QUESTIONS 115



Lisa Burgess/McGraw-Hill Education



5 Control of Microbial Growth 117

A Glimpse of History 117

Key Terms 117

5.1 Approaches to Control 117

Principles of Control 118
Situational Considerations 118

5.2 Selecting an Antimicrobial Procedure 121

Types of Microbes 121
Number of Microbes 121
Environmental Conditions 122
Risk for Infection 122
Composition of the Item 122

5.3 Physical Methods Used to Destroy or Remove Microorganisms and Viruses 122

Moist Heat 122
Dry Heat 124
Filtration 124
Irradiation 125
High Pressure 126

5.4 Chemical Methods Used to Destroy Microorganisms and Viruses 127

Selecting the Appropriate Germicidal Chemical 127
Categories of Germicidal Potency 128
Classes of Germicidal Chemicals 128

5.5 Preservation of Perishable Products 132

Chemical Preservatives 132
Low-Temperature Storage 132
Reducing the Available Water 132

FOCUS ON A CASE 5.1 120

FOCUS ON THE FUTURE 5.1: Too Much of a Good Thing? 133

SUMMARY 134

REVIEW QUESTIONS 135

6 Microbial Metabolism: Fueling Cell Growth 137

A Glimpse of History 137

Key Terms 137

6.1 Overview of Microbial Metabolism 138

Energy 138
Components of Metabolic Pathways 140
Precursor Metabolites 143
Catabolism 144

6.2 Enzymes 147

Mechanisms and Consequences of Enzyme Action 147
Cofactors 147
Environmental Factors That Influence Enzyme Activity 148



Arthur Tilley/Getty Images



©Comstock/PunchStock

Allosteric Regulation 149

Enzyme Inhibition 150

6.3 The Central Metabolic Pathways 151

Glycolysis 152
Pentose Phosphate Pathway 152
Transition Step and Tricarboxylic Acid (TCA) Cycle 152

6.4 Cellular Respiration 155

The Electron Transport Chain (ETC)—Generating a Proton Motive Force 155
ATP Synthase—Using the Proton Motive Force to Synthesize ATP 157
ATP Yield of Aerobic Respiration in Prokaryotes 159

6.5 Fermentation 160

6.6 Catabolism of Organic Compounds Other Than Glucose 162

Polysaccharides and Disaccharides 162
Lipids 163
Proteins 164

6.7 Chemolithotrophs 164

6.8 Photosynthesis 165

Light-Dependent Reactions 165
Light-Independent Reactions 167

6.9 Carbon Fixation 168

Calvin Cycle 168

6.10 Anabolic Pathways—Synthesizing Subunits from Precursor Molecules 169

Lipid Synthesis 170
Amino Acid Synthesis 170
Nucleotide Synthesis 171

FOCUS ON A CASE 6.1 162

FOCUS YOUR PERSPECTIVE 6.1: Mining with Microbes 165

FOCUS ON THE FUTURE 6.1: Fueling the Future 171

SUMMARY 172

REVIEW QUESTIONS 173

7 The Blueprint of Life, from DNA to Protein 175

A Glimpse of History 175

Key Terms 175

7.1 Overview 176

Characteristics of DNA 176
Characteristics of RNA 177
Regulating Gene Expression 178

7.2 DNA Replication 179

7.3 Gene Expression in Bacteria 182



Molekuul/SPL/age fotostock

Transcription 182
Translation 184

7.4 Differences Between Eukaryotic and Prokaryotic Gene Expression 189

7.5 Sensing and Responding to Environmental Fluctuations 191

Signal Transduction 191
Natural Selection 192

7.6 Bacterial Gene Regulation 193

Mechanisms to Control Transcription 194
The *lac* Operon as a Model 196

7.7 Eukaryotic Gene Regulation 198

7.8 Genomics 199

Analyzing a Prokaryotic DNA Sequence 199
Metagenomics 200

FOCUS ON A CASE 7.1 192

FOCUS YOUR PERSPECTIVE 7.1: RNA: The First Macromolecule? 190

FOCUS ON THE FUTURE 7.1: Gems in the Genomes? 200

SUMMARY 200

REVIEW QUESTIONS 201

8 Bacterial Genetics 203

A Glimpse of History 203

Key Terms 203

8.1 Genetic Change in Bacteria 203



Dr. Gopal Murti/Science Source

MUTATION AS A MECHANISM OF GENETIC CHANGE

8.2 Spontaneous Mutations 205

Base Substitution 205
Deletion or Addition of Nucleotides 206
Transposons (Jumping Genes) 206

8.3 Induced Mutations 207

Chemical Mutagens 207
Transposition 208
Radiation 208

8.4 Repair of Damaged DNA 209

Repair of Errors in Nucleotide Incorporation 210
Repair of Damaged Nucleobases 210
Repair of Thymine Dimers 210
SOS Repair 211

8.5 Mutant Selection 212

Direct Selection 212
Indirect Selection 212
Screening for Possible Carcinogens 214

HORIZONTAL GENE TRANSFER AS A MECHANISM OF GENETIC CHANGE

8.6 Overview of Horizontal Gene Transfer 215

8.7 Bacterial Transformation 216

Competence 217
The Process of Natural Transformation 218

8.8 Transduction 220

8.9 Conjugation 221

Plasmid Transfer 221
Chromosome Transfer 222
F' Donors 223

8.10 Genome Variability 225

Mobile Genetic Elements (MGEs) 225

8.11 Bacterial Defenses Against Invading DNA 228

Restriction-Modification Systems 228
CRISPR Systems 228

FOCUS ON A CASE 8.1 227

FOCUS YOUR PERSPECTIVE 8.1: The Biological Function of DNA: A Discovery Ahead of Its Time 219

FOCUS YOUR PERSPECTIVE 8.2: Bacteria Can Conjugate with Plants: A Natural Case of Genetic Engineering 224

SUMMARY 229

REVIEW QUESTIONS 231

9 Biotechnology 232

A Glimpse of History 232

Key Terms 232

9.1 Fundamental Tools Used in Biotechnology 234

Restriction Enzymes 234
Reverse Transcriptase 235
DNA Gel Electrophoresis 236

9.2 Molecular Cloning 237

The Cloning Process—A Simplified View 237
Applications of Molecular Cloning 237
Creating a DNA Library—A Detailed View of the Cloning Process 237

9.3 CRISPR-Cas Technologies 240

Applications of CRISPR-Cas Technologies 240

9.4 DNA Sequencing 241

Applications of DNA Sequencing 242
High-Throughput Sequencing Methods 242
RNA-Seq (RNA Sequencing) 243

9.5 Polymerase Chain Reaction (PCR) 243

Applications of PCR 243
The PCR Method 244



atic12/123RF

- 9.6 Probe Technologies 249**
 Colony Blotting 249
 Fluorescence In Situ Hybridization (FISH) 250
 DNA Microarrays 250

9.7 Concerns Regarding Biotechnology 251

FOCUS ON A CASE 9.1 248

FOCUS YOUR PERSPECTIVE 9.1: The COVID-19 Response—The Power of Biotechnology 244

FOCUS ON THE FUTURE 9.1: Precision Medicine 252

SUMMARY 252

REVIEW QUESTIONS 253

PART II

The Microbial World

10 Identifying and Classifying Microorganisms 255

A Glimpse of History 255

Key Terms 255

10.1 Principles of Taxonomy 256

Strategies Used to Identify Microorganisms 256

Strategies Used to Classify Microorganisms 256

Nomenclature 257

10.2 Identification Methods Based on Phenotype 259

Microscopic Morphology 259

Culture Characteristics 260

Metabolic Capabilities 260

Serological Characteristics 262

Protein Profile 262

10.3 Identification Methods Based on Genotype 264

Detecting Specific Nucleotide Sequences 264

Sequencing Ribosomal RNA Genes 264

Whole Genome Sequencing 265

10.4 Characterizing Strain Differences 266

Biochemical Typing 266

Serological Typing 266

Whole Genome Sequencing 266

Phage Typing 267

Antibiograms 267

10.5 Classifying Microorganisms 269

Sequence Analysis of Ribosomal Components 269

DNA-DNA Hybridization (DDH) 270

Sequence Analysis of Genomes 270

G + C Content 270

Phenotypic Methods 271



Diane Keough/Moment/Getty Images

FOCUS ON A CASE 10.1 268

FOCUS ON THE FUTURE 10.1: Pushing the Limits of MALDI-TOF MS 271

SUMMARY 272

REVIEW QUESTIONS 273

11 The Diversity of Bacteria and Archaea 274

A Glimpse of History 274

Key Terms 274



Heather Davies/Science Photo Library/Getty Images

METABOLIC DIVERSITY

11.1 Anaerobic Chemotrophs 275

Anaerobic Chemolithotrophs 275

Anaerobic Chemoorganotrophs—Anaerobic Respiration 276

Anaerobic Chemoorganotrophs—Fermentation 276

11.2 Anoxygenic Phototrophs 277

Purple Bacteria 278

Green Bacteria 278

Other Anoxygenic Phototrophs 279

11.3 Oxygenic Phototrophs 279

Cyanobacteria 279

11.4 Aerobic Chemolithotrophs 280

Sulfur-Oxidizing Bacteria 281

Nitrifiers 281

Hydrogen-Oxidizing Bacteria 282

11.5 Aerobic Chemoorganotrophs 282

Obligate Aerobes 282

Facultative Anaerobes 284

ECOPHYSIOLOGICAL DIVERSITY

11.6 Thriving in Terrestrial Environments 286

Bacteria That Form a Resting Stage 286

Bacteria That Associate with Plants 287

11.7 Thriving in Aquatic Environments 289

Sheathed Bacteria 289

Prosthecate Bacteria 289

Bacteria That Derive Nutrients from Other Organisms 290

Bacteria That Move by Unusual Mechanisms 291

Bacteria That Form Storage Granules 292

11.8 Animals as Habitats 293

Bacteria that Inhabit the Skin 293

Bacteria That Inhabit Mucous Membranes 294

Obligate Intracellular Parasites 296

11.9 Archaea That Thrive in Extreme Conditions 299

Extreme Halophiles 299

Extreme Thermophiles 300

FOCUS ON A CASE 11.1 294

FOCUS ON THE FUTURE 11.1: Astrobiology: Searching for Life Beyond Earth 301

SUMMARY 301

REVIEW QUESTIONS 303

12 The Eukaryotic Members of the Microbial World 305

A Glimpse of History 305

Key Terms 305

12.1 Fungi 306

Characteristics of Fungi 307

Classification of Fungi 309

Groups of Medically Important Fungi 310

Economic Importance of Fungi 311

Symbiotic Relationships of Fungi 312

12.2 Protozoa 313

Characteristics of Protozoa 313

Groups of Medically Significant Protozoa 314

Other Protozoan Groups 315

12.3 Algae 318

Characteristics of Algae 318

Types of Algae 319

Exceptions to the Rule 320

12.4 Multicellular Parasites: Helminths 321

Life Cycles and Transmission of Helminths 321

Roundworms (Nematodes) 322

Tapeworms (Cestodes) 322

Flukes (Trematodes) 324

12.5 Arthropods 325

FOCUS ON A CASE 12.1 317

FOCUS YOUR PERSPECTIVE 12.1: What Causes River Blindness? 322

SUMMARY 326

REVIEW QUESTIONS 327

13 Viruses, Viroids, and Prions 329

A Glimpse of History 329

Key Terms 329

13.1 General Characteristics of Viruses 330

Viral Structure 330

Viral Taxonomy 330

13.2 Bacteriophages 335

Lytic Phage Infections: T4 Phage as a Model 335

Temperate Phage Infections: Lambda Phage as a Model 337

Filamentous Phage Infections: M13 Phage as a Model 338

13.3 The Roles of Bacteriophages in Horizontal Gene Transfer 339

Generalized Transduction 339

Specialized Transduction 339

13.4 Methods Used to Study Bacteriophages 340

13.5 Animal Virus Replication 341

Attachment 341

Entry and Uncoating 341

Synthesis of Viral Proteins and Replication of the Genome 342

Assembly (Maturation) 345

Release 346

13.6 Categories of Animal Virus Infections 347

Acute Infections 347

Persistent Infections 347

13.7 Viruses and Human Tumors 349

Cancer-Causing Viruses 349

Cancer-Fighting Viruses 350

13.8 Cultivating and Quantitating Animal Viruses 351

Cultivating Animal Viruses 351

Quantitating Animal Viruses 352

13.9 Plant Viruses 353

13.10 Other Infectious Agents: Viroids and Prions 354

Viroids 354

Prions 354

FOCUS ON A CASE 13.1 346

FOCUS YOUR PERSPECTIVE 13.1: Microbe Mimicker 335

FOCUS ON THE FUTURE 13.1: The Potential of Phage Therapy 356

SUMMARY 357

REVIEW QUESTIONS 358

PART III

Microorganisms and Humans

14 The Innate Immune Response 360

A Glimpse of History 360

Key Terms 360

14.1 Overview of the Innate Immune Defenses 361

14.2 First-Line Defenses 362


Physical Barriers 363

Antimicrobial Substances 363

Normal Microbiota (Flora) 364



Steve Gschmeissner/ Science Photo Library/Getty Images



Source: National Institute of Allergy and Infectious Diseases (NIAID)/CDC



Science Photo Library/Alamy Stock Photo

14.3 The Cells of the Immune System 364

- Granulocytes 365
- Mononuclear Phagocytes 366
- Dendritic Cells 367
- Lymphocytes 367

14.4 Cell Communication 368

- Surface Receptors 368
- Cytokines 368
- Adhesion Molecules 368

14.5 Pattern Recognition Receptors (PRRs) 369

- Pattern Recognition Receptors (PRRs) That Monitor a Cell's Surroundings 370
- Pattern Recognition Receptors (PRRs) That Monitor Material Ingested by a Cell 370
- Pattern Recognition Receptors (PRRs) That Monitor a Cell's Cytoplasm 371
- An Outcome of Cytoplasmic Pattern Recognition: The Interferon Response 371

14.6 The Complement System 372

- Complement System Activation 373
- Effector Functions of the Complement System 374
- Regulation of the Complement System 374

14.7 Phagocytosis 375

- The Process of Phagocytosis 375
- Characteristics of Macrophages 376
- Characteristics of Neutrophils 377

14.8 The Inflammatory Response 377

- The Inflammatory Process 378
- Damaging Effects of Inflammation 378
- Cell Death and the Inflammatory Response 380

14.9 Fever 380**FOCUS ON A CASE 14.1** 381

FOCUS YOUR PERSPECTIVE 14.1: For *Schistosoma*, the Inflammatory Response Delivers 380

SUMMARY 382

REVIEW QUESTIONS 383

15 The Adaptive Immune Response 385**A Glimpse of History 385****Key Terms 385****15.1 Overview of the Adaptive Immune Response 386**

- Cell-Mediated Immunity 388
- Humoral Immunity 389
- The Nature of Antigens 389
- The Lymphatic System 391
- The Big Picture Summary 392

15.2 Clonal Selection and Expansion of Lymphocytes 394**15.3 The T-Cell Response: Cell-Mediated Immunity 396**

- General Characteristics of T Cells 396
- Activation of T Cells 397
- Effector Functions of T_C (CD8) Cells 398
- Effector Functions of T_H (CD4) Cells 399

15.4 The B-Cell Response: Humoral Immunity 402

- General Characteristics of B cells 402
- B-Cell Activation 402
- Characteristics of Antibodies 402
- Evolution of the Humoral Response to T-Dependent Antigens 404
- The Response to T-Independent Antigens 407

15.5 Lymphocyte Development 408

- Generation of Diversity 408
- Negative Selection of Self-Reactive B Cells 408
- Positive and Negative Selection of Self-Reactive T Cells 408

15.6 Natural Killer (NK) Cells 409**FOCUS ON A CASE 15.1** 410

FOCUS YOUR PERSPECTIVE 15.1: What Flavors Are Your Major Histocompatibility Complex (MHC) Molecules? 401

SUMMARY 411

REVIEW QUESTIONS 413

16 Host-Microbe Interactions 415**A Glimpse of History 415****Key Terms 415****MICROBES, HEALTH, AND DISEASE**

NIAID, NIH, Rocky Mountain Laboratories

16.1 The Anatomical Barriers as Ecosystems 416**16.2 The Human Microbiome 416**

- Composition of the Microbiome 417
- Beneficial Roles of the Human Microbiome 417

16.3 Principles of Infectious Disease 418

- Pathogenicity 418
- Characteristics of Infectious Disease 419

16.4 Determining the Cause of an Infectious Disease 420

- Koch's Postulates 420
- Molecular Koch's Postulates 421

MECHANISMS OF PATHOGENESIS**16.5 Establishing Infection 422**

- Adherence 422
- Colonization 422
- Delivering Effector Proteins to Host Cells 423

16.6 Invasion—Breaching the Anatomical Barriers 423

- Penetrating the Skin 423
- Penetrating Mucous Membranes 423

16.7 Avoiding the Host Defenses 424

- Hiding Within a Host Cell 424
- Avoiding Destruction by Phagocytes 425
- Avoiding Killing by Complement System Proteins 426
- Avoiding Recognition by Antibodies 427

16.8 Damage to the Host 427

- Exotoxins 427
- Endotoxin and Other Bacterial Cell Wall Components 430
- Damaging Effects of the Immune Response 432

16.9 Mechanisms of Viral Pathogenesis 433

- Binding to Host Cells and Invasion 433
- Avoiding Immune Responses 433
- Damage to the Host 434

16.10 Mechanisms of Eukaryotic Pathogenesis 434

- Fungi 434
- Protozoa and Helminths 435

FOCUS ON A CASE 16.1 429**FOCUS ON THE FUTURE 16.1:** The Potential of Probiotics 435

SUMMARY 436

REVIEW QUESTIONS 437

17 Applications of Immune Responses 439**A Glimpse of History 439**

Key Terms 439

IMMUNIZATION AND IMMUNOTHERAPY**17.1 Principles of Immunization 440**

- Active Immunity 440
- Passive Immunity 440

17.2 Vaccines and Immunization Procedures 441

- Attenuated Vaccines 441
- Inactivated Vaccines 442
- The Importance of Vaccines 443
- An Example of Vaccination Strategy—
The Campaign to Eliminate Poliomyelitis 444

17.3 Immunotherapies 446

- Immunotherapies for Cancer 446
- Immunotherapies for Immunological Disorders 449
- Immunotherapies for Infectious Diseases 450

IMMUNOLOGICAL TESTING**17.4 Principles of Immunoassays 451**

- Quantifying Antigen-Antibody Reactions 452
- Obtaining Known Antibodies 452

17.5 Common Types of Immunoassays 453

- Immunoassays That Use Labeled Antibodies 454
- Immunoassays That Involve Visible Antigen-Antibody Aggregates 457

FOCUS ON A CASE 17.1 453**FOCUS YOUR PERSPECTIVE 17.1:** Obtaining Monoclonal Antibodies 449

SUMMARY 461

REVIEW QUESTIONS 462

18 Immunological Disorders 464**A Glimpse of History 464**

Key Terms 464

18.1 Hypersensitivities 464

- Type I Hypersensitivities:
Immediate IgE-Mediated 465
- Type II Hypersensitivities:
Cytotoxic 468
- Type III Hypersensitivities: Immune Complex–Mediated 470
- Type IV Hypersensitivities: Delayed-Type
Cell-Mediated 471



©bubutu/Shutterstock

18.2 Autoimmune Disease 473

- Systemic Autoimmune Diseases 474
- Organ-Specific Autoimmune Diseases 474

18.3 Immunodeficiency Disorders 476

- Primary Immunodeficiencies 476
- Secondary Immunodeficiencies 477

FOCUS ON A CASE 18.1 476**FOCUS YOUR PERSPECTIVE 18.1:** The Fetus as an Allograft 473

SUMMARY 478

REVIEW QUESTIONS 479

19 Epidemiology 481**A Glimpse of History 481**

Key Terms 481

19.1 Basic Concepts of Epidemiology 482

- 19.2 Chain of Infection 483**
- Reservoirs of Infection 483
- Portals of Exit 484
- Disease Transmission 484
- Portals of Entry 487

19.3 Factors That Influence the Epidemiology of Disease 487

- The Dose 488
- The Incubation Period 488
- The Host Population 488
- The Environment 488



Source: CDC/James Gathany

19.4 Epidemiological Studies 489

- Descriptive Studies 489
- Analytical Studies 490
- Experimental Studies 491

19.5 Infectious Disease Surveillance 491

- National Disease Surveillance Network 493
- Worldwide Disease Surveillance 494
- Reduction and Eradication of Disease 494

19.6 Emerging Infectious Diseases 495**19.7 Healthcare-Associated Infections 496**

- Reservoirs of Infectious Agents in Healthcare Settings 496
- Transmission of Infectious Agents in Healthcare Settings 498
- Preventing Healthcare-Associated Infections 498

FOCUS ON A CASE 19.1 492**FOCUS YOUR PERSPECTIVE 19.1:** Standard Precautions—Protecting Patients and Healthcare Personnel 499**FOCUS ON THE FUTURE 19.1:** Maintaining Vigilance Against Bioterrorism 500

SUMMARY 501

REVIEW QUESTIONS 502

20 Antimicrobial Medications 504**A Glimpse of History 504****Key Terms 504****20.1 History and Development of Antimicrobial Medications 504**

- Discovery of Antimicrobial Medications 505
- Discovery of Antibiotics 505
- Development of New Antimicrobial Medications 505

20.2 Characteristics of Antimicrobial Medications 507

- Selective Toxicity 507
- Antimicrobial Action 507
- Spectrum of Activity 507
- Effects of Antimicrobial Combinations 507
- Tissue Distribution, Metabolism, and Excretion of the Medication 507
- Adverse Effects 508
- Resistance to Antimicrobials 508

20.3 Mechanisms of Action of Antibacterial Medications 508

- Inhibit Cell Wall Synthesis 509
- Inhibit Protein Synthesis 512
- Inhibit Nucleic Acid Synthesis 513
- Interfere with Metabolic Pathways 514
- Interfere with Cell Membrane Integrity 514
- Effective Against *Mycobacterium tuberculosis* 514

20.4 Antimicrobial Susceptibility Testing 516

- Conventional Disc Diffusion Method 516
- Minimum Inhibitory and Minimum Bactericidal Concentrations (MIC and MBC) 517
- Commercial Modifications of Antimicrobial Susceptibility Testing 518

20.5 Resistance to Antimicrobial Medications 519

- Mechanisms of Acquired Resistance 519
- Acquisition of Resistance 521
- Examples of Emerging Resistance 521
- Preventing Resistance 523

20.6 Mechanisms of Action of Antiviral Medications 526

- Prevent Viral Entry 526
- Interfere with Viral Uncoating 526
- Interfere with Nucleic Acid Synthesis 527
- Prevent Genome Integration 527
- Prevent Assembly and Release of Viral Particles 527

20.7 Mechanisms of Action of Antifungal Medications 529

- Interfere with Cytoplasmic Membrane Synthesis and Function 529
- Interfere with Cell Wall Synthesis 529
- Interfere with Cell Division 530
- Interfere with Nucleic Acid Synthesis 530
- Interfere with Protein Synthesis 530


20.8 Mechanisms of Action of Antiprotozoan and Antihelminthic Medications 531**FOCUS ON A CASE 20.1 525****FOCUS YOUR PERSPECTIVE 20.1:** Using Diffusion Tests to Measure the Concentration of an Antimicrobial Medication in Blood or Other Body Fluids 519**FOCUS ON THE FUTURE 20.1:** The Race to Develop COVID-19 Treatments 532

SUMMARY 533

REVIEW QUESTIONS 534

PART IV**Infectious Diseases****21 Respiratory System Infections 536****A Glimpse of History 536****Key Terms 536****21.1 Anatomy, Physiology, and Ecology of the Respiratory System 536**

- The Upper Respiratory Tract 537
- The Lower Respiratory Tract 539



Source: James Gathany/CDC



Centers for Disease Control and Prevention

UPPER RESPIRATORY TRACT INFECTIONS

21.2 Bacterial Infections of the Upper Respiratory System 540

- Pink Eye, Earache, and Sinus Infections 540
- Streptococcal Pharyngitis (“Strep Throat”) 541
- Post-Streptococcal Sequelae 544
- Diphtheria 545

21.3 Viral Infections of the Upper Respiratory System 548

- The Common Cold 548
- Adenovirus Respiratory Tract Infections 549

LOWER RESPIRATORY TRACT INFECTIONS

FOCUS ON PNEUMONIA 551

21.4 Bacterial Infections of the Lower Respiratory System 552

- Pneumococcal Pneumonia 552
- Klebsiella* Pneumonia 553
- Mycoplasma Pneumonia (“Walking Pneumonia”) 554
- Pertussis (“Whooping Cough”) 555
- Tuberculosis (“TB”) 557
- Legionnaires’ Disease (*Legionella* Pneumonia) 561
- Inhalation Anthrax 563

21.5 Viral Infections of the Lower Respiratory System 565

- Influenza (“Flu”) 565
- Respiratory Syncytial Virus (RSV) Infections 568
- Coronavirus Infections: COVID-19, SARS, and MERS 569
- Hantavirus Pulmonary Syndrome 572

21.6 Fungal Infections of the Lower Respiratory System 573

- Coccidioidomycosis (“Valley Fever”) 574
- Histoplasmosis (“Spelunker’s Disease”) 575
- Pneumocystis* Pneumonia (PCP) 576

FOCUS ON A CASE 21.1 546

FOCUS YOUR PERSPECTIVE 22.1: A Global Lesson in Microbiology: The COVID-19 Pandemic 571

DISEASES IN REVIEW 21.1: Respiratory System Diseases 578

SUMMARY 579

REVIEW QUESTIONS 580

22 Skin Infections 582


A Glimpse of History 582

Key Terms 582

22.1 Anatomy, Physiology, and Ecology of the Skin 582

22.2 Bacterial Diseases of the Skin 584

- Acne Vulgaris 584
- Hair Follicle Infections 586
- Staphylococcal Scalded Skin Syndrome 589



Source: Janice Carr/CDC

Impetigo 590

Rocky Mountain Spotted Fever 591

Cutaneous Anthrax 593

22.3 Viral Diseases of the Skin 594

- Varicella (Chickenpox) 595
- Rubeola (Measles) 597
- Rubella (German Measles) 600
- Other Viral Rashes of Childhood 601
- Warts 603

22.4 Fungal Diseases of the Skin 603

- Superficial Cutaneous Mycoses 603
- Other Fungal Diseases 604

FOCUS ON A CASE 22.1 600

FOCUS YOUR PERSPECTIVE 22.1: The Ghost of Smallpox: An Evil Shade 598

DISEASES IN REVIEW 22.1: Common Bacterial, Viral, and Fungal Skin Diseases 606

SUMMARY 607

REVIEW QUESTIONS 607

23 Wound Infections 609

A Glimpse of History 609

Key Terms 609

23.1 Anatomy, Physiology, and Ecology of Wounds 609

- Wound Abscesses 611

23.2 Common Bacterial Infections of Wounds 612

- Staphylococcal Wound Infections 612
- Group A Streptococcal “Flesh-Eating Disease” 613
- Pseudomonas aeruginosa* Infections 614

23.3 Diseases Due to Anaerobic Bacterial Wound Infections 617

- Tetanus (“Lockjaw”) 617
- Clostridial Myonecrosis (“Gas Gangrene”) 619

23.4 Bacterial Infections of Bite Wounds 622

- Human Bites 622
- Pasteurella multocida* Bite Wound Infections 623
- Bartonellosis (“Cat Scratch Disease”) 624
- Other Bacterial Bite Wound Infections 625

23.5 Fungal Wound Infections 625

- Sporotrichosis (“Rose Gardener’s Disease”) 625

FOCUS ON A CASE 23.1 622

FOCUS YOUR PERSPECTIVE 23.1: Infection Caused by a Human “Bite” 624

DISEASES IN REVIEW 23.1: Wound Infections 627

SUMMARY 628

REVIEW QUESTIONS 628



©Garry Watson/Science Source

24 Digestive System Infections 630


A Glimpse of History 630

Key Terms 630

24.1 Anatomy, Physiology, and Ecology of the Digestive System 631

The Upper Digestive System 632

The Lower Digestive System 633



Steve Gschmeissner/SPL/Science Source

UPPER DIGESTIVE SYSTEM INFECTIONS

24.2 Bacterial Diseases of the Upper Digestive System 634

Dental Caries 635

Periodontal Disease 636

Acute Necrotizing Ulcerative Gingivitis 637

Helicobacter pylori Gastritis 639

24.3 Viral Diseases of the Upper Digestive System 641

Oral Herpes (Cold Sores) 641

Mumps 642

LOWER DIGESTIVE SYSTEM INFECTIONS

FOCUS ON DIARRHEAL DISEASES 644

24.4 Bacterial Diseases of the Lower Digestive System 644

Cholera 645

Shigellosis 647

Escherichia coli Gastroenteritis 648

Salmonella Gastroenteritis 650

Enteric Fever (Typhoid and Paratyphoid) 652

Campylobacteriosis 653

Clostridioides (Clostridium) difficile Infection (CDI) 654

24.5 Viral Diseases of the Lower Digestive System—Intestinal Tract 656

Rotavirus Gastroenteritis 656

Norovirus Gastroenteritis 656

24.6 Viral Diseases of the Lower Digestive System—Liver 658

Hepatitis A 658

Hepatitis B 659

Hepatitis C 661

24.7 Protozoan Diseases of the Lower Digestive System 662

Giardiasis 662

Cryptosporidiosis (“Crypto”) 663

Cyclosporiasis 665

Amebiasis 666

FOCUS ON A CASE 24.1 640

DISEASES IN REVIEW 24.1: Digestive System Diseases 668

SUMMARY 669

REVIEW QUESTIONS 670

25 Blood and Lymphatic Infections 672

A Glimpse of History 672

Key Terms 672


25.1 Anatomy, Physiology, and Ecology of the Blood and Lymphatic Systems 673

The Heart 673

Blood Vessels 673

Lymphatics (Lymphatic Vessels) 673

Spleen 674



Steve Gschmeissner/Science Photo Library/Alamy Stock Photo

25.2 Bacterial Diseases of the Blood and Lymphatic Systems 674

Infective Endocarditis 674

Sepsis and Septic Shock 675

Plague (“Black Death”) 676

Lyme Disease 678

Vibrio vulnificus Infection 682

Tularemia (“Rabbit Fever” or “Deer Fly Fever”) 683

Brucellosis (“Undulant Fever” or “Bang’s Disease”) 684

25.3 Viral Diseases of the Blood and Lymphatic Systems 686

Infectious Mononucleosis (“Mono” or “Kissing Disease”) 686

Ebola Disease (EBOD) and Marburg Disease (MARD) 688

Yellow Fever 689

Dengue and Severe Dengue 690

Chikungunya 691

Zika Virus Disease 692

25.4 Protozoan Diseases of the Blood and Lymphatic Systems 694

Malaria 694

FOCUS ON A CASE 25.1 692

DISEASES IN REVIEW 25.1: Blood and Lymphatic Infections 699

SUMMARY 700


REVIEW QUESTIONS 701

26 Nervous System Infections 703

A Glimpse of History 703

Key Terms 703

26.1 Anatomy, Physiology, and Ecology of the Nervous System 703



Science Picture Co/Getty Images

CENTRAL NERVOUS SYSTEM INFECTIONS

FOCUS ON MENINGITIS 706

26.2 Bacterial Diseases of the Central Nervous System 706

Pneumococcal Meningitis 707

Meningococcal Meningitis 708
Haemophilus influenzae Meningitis 709
 Neonatal Meningitis 710
 Listeriosis 711

26.3 Viral Diseases of the Central Nervous System 713

Viral Meningitis 713
 West Nile and Other Types of Viral Encephalitis 714
 Poliomyelitis 715
 Rabies 718

26.4 Fungal Diseases of the Central Nervous System 721

Cryptococcal Meningoencephalitis 721

26.5 Protozoan Diseases of the Central Nervous System 723

African Trypanosomiasis (“African Sleeping Sickness”) 723
 Toxoplasmosis 724
 Primary Amebic Meningoencephalitis (PAM) 726

26.6 Diseases Caused by Prions 727

Transmissible Spongiform Encephalopathies in Humans 728

PERIPHERAL NERVOUS SYSTEM INFECTIONS

26.7 Bacterial Diseases of the Peripheral Nervous System 729

Hansen’s Disease (Leprosy) 729
 Botulism 731

FOCUS ON A CASE 26.1 711

FOCUS YOUR PERSPECTIVE 26.1: Rabies Survivors! 721

DISEASES IN REVIEW 26.1: Nervous System Diseases 734

SUMMARY 735

REVIEW QUESTIONS 736


27 Genitourinary Tract Infections 738

A Glimpse of History 738

Key Terms 738

27.1 Anatomy, Physiology, and Ecology of the Genitourinary System 738

The Urinary System 738
 The Genital System 739



Science Photo Library - PASIEKA/Getty Images

27.2 Urinary Tract Infections 740

Bacterial Cystitis (“Bladder Infection”) 740
 Leptospirosis 741

27.3 Genital System Diseases 744

Bacterial Vaginosis (BV) 745
 Vulvovaginal Candidiasis (VVC) 746
 Staphylococcal Toxic Shock Syndrome 746

SEXUALLY TRANSMITTED INFECTIONS

FOCUS ON SEXUALLY TRANSMITTED INFECTIONS 748

27.4 Bacterial STIs 748

Chlamydial Infections 748
 Gonorrhea 751
Mycoplasma genitalium Infections 753
 Syphilis 755
 Chancroid 758

27.5 Viral STIs 760

Genital Herpes 760
 Human Papillomavirus STIs: Genital Warts and Cervical Cancer 761
 HIV/AIDS 763

27.6 Protozoan STIs 771

Trichomoniasis (“Trich”) 771

FOCUS ON A CASE 27.1 742

FOCUS YOUR PERSPECTIVE 27.1: Conquering Syphilis 759

FOCUS ON THE FUTURE 27.1: Getting Control of Sexually Transmitted Infections 772

DISEASES IN REVIEW 27.1: Genitourinary Infections 773

SUMMARY 774

REVIEW QUESTIONS 775

PART V

Applied Microbiology

28 Microbial Ecology 777

A Glimpse of History 777

Key Terms 777

28.1 Principles of Microbial Ecology 778

Nutrient Acquisition 778
 Microbes in Low-Nutrient Environments 778
 Microbial Competition 779
 Microorganisms and Environmental Changes 779
 Microbial Communities 780

28.2 Studying Microbial Ecology 781

28.3 Aquatic Habitats 782

Marine Environments 782
 Freshwater Environments 783
 Specialized Aquatic Environments 783

28.4 Terrestrial Habitats 783

Characteristics of Soil 784
 Microorganisms in Soil 784

28.5 Biogeochemical Cycling and Energy Flow 785

Carbon Cycle 785



Photo by Tim McCabe, USDA Natural Resource Conservation Service

Nitrogen Cycle 786
 Sulfur Cycle 788
 Phosphorus Cycle and Other Cycles 788
 Energy Sources for Ecosystems 789

28.6 Mutualistic Relationships Between Microorganisms and Eukaryotes 790

Mycorrhizas 790
 Symbiotic Nitrogen-Fixers and Plants 790
 Microorganisms and Herbivores 792

FOCUS ON A CASE 28.1 792

SUMMARY 793

REVIEW QUESTIONS 794

29 Environmental Microbiology: Treatment of Water, Wastes, and Polluted Habitats 796

A Glimpse of History 796

Key Terms 796

29.1 Microbiology of Wastewater Treatment 797

Biochemical Oxygen Demand (BOD) 797

Municipal Wastewater Treatment Methods 797
 Individual Wastewater Treatment Systems 800

29.2 Drinking Water Treatment and Testing 801

Water Treatment Processes 801
 Water Testing 802

29.3 Microbiology of Solid Waste Treatment 805

Sanitary Landfills for Solid Waste Disposal 805
 Municipal and Backyard Composting—Alternative to Landfills 805

29.4 Microbiology of Bioremediation 806

Pollutants 806
 Strategies of Bioremediation 807

FOCUS ON A CASE 29.1 804

SUMMARY 808

REVIEW QUESTIONS 808



Robert Glusic/Getty Images

30 Food Microbiology 810

A Glimpse of History 810

Key Terms 810

30.1 Factors Influencing the Growth of Microorganisms in Foods 811

Intrinsic Factors 811
 Extrinsic Factors 812



Images by Tang Ming Tung/Getty Images

30.2 Microorganisms in Food and Beverage Production 812

Lactic Acid Fermentations by the Lactic Acid Bacteria 813
 Alcoholic Fermentations by Yeast 815
 Changes Due to Mold Growth 817

30.3 Food Spoilage 818

Common Spoilage Bacteria 818
 Common Spoilage Fungi 818

30.4 Foodborne Illness 819

Foodborne Intoxication 819
 Foodborne Infection 819

30.5 Food Preservation 822

FOCUS ON A CASE 30.1 821

FOCUS YOUR PERSPECTIVE 30.1: Botox for Beauty and Pain Relief 821

SUMMARY 823

REVIEW QUESTIONS 824

APPENDIX I Microbial Mathematics A-1

APPENDIX II Pronunciation Key for Bacterial, Fungal, Protozoan, and Viral Names A-2

APPENDIX III Metabolic Pathways A-4


APPENDIX IV Answers to Multiple Choice Questions A-7

APPENDIX V Microbial Terminology A-8

GLOSSARY/INDEX GI-1

1

Humans and the Microbial World



Drawings that van Leeuwenhoek made in 1683 of microorganisms he saw through his single-lens microscope. He also observed organism B moving from position C to D. (INTERFOTO/Alamy, Stock Photo)

A Glimpse of History

Microbiology as a science was born in 1674 when Antonie van Leeuwenhoek, an inquisitive Dutch fabric merchant, looked at a drop of lake water through a glass lens he had carefully made. Although many people before him had used curved glass to magnify objects, Leeuwenhoek's skilled hands made a lens that uncovered a startling and amazing sight—the world of microbes. As van Leeuwenhoek wrote in a letter to the Royal Society of London, he saw

Very many little animalcules, whereof some were roundish, while others a bit bigger consisted of an oval. On these last, I saw two little legs near the head, and two little fins at the hind most end of the body. Others were somewhat longer than an oval, and these were very slow a-moving, and few in number. These animalcules had diverse colours, some being whitish and transparent; others with green and very glittering little scales, others again were green in the middle, and before and behind white;

KEY TERMS

Domain The highest level in biological classification. There are three domains: Bacteria, Archaea, and Eukarya.

Eukaryote Organism composed of one or more eukaryotic cells; members of the domain Eukarya are eukaryotes.

Eukaryotic Cell Cell type characterized by a membrane-bound nucleus.

Prion An acellular infectious agent consisting only of protein.

Prokaryote Single-celled organism consisting of a prokaryotic cell; members of the domains Bacteria and Archaea are prokaryotes.

Prokaryotic Cell Cell type characterized by the lack of a membrane-bound nucleus.

Viroid An acellular infectious agent consisting only of RNA.

Virus An acellular infectious agent consisting of nucleic acid surrounded by a protein coat.

others yet were ashd grey. And the motion of most of these animalcules in the water was so swift, and so various, upwards, downwards, and round about, that 'twas wonderful to see.

Before van Leeuwenhoek made these observations, Robert Hooke, an English microscopist, saw another kind of microorganism. In 1665, he described what he called a “microscopical mushroom.” His drawing was so accurate that his specimen could later be identified as a common bread mold. Hooke also described how to make the kind of microscope that van Leeuwenhoek constructed almost 10 years later. Both men deserve equal credit for revealing the world of microbes—a world you are about to study.

Microbiology is the study of an amazing world made up of members too small to be seen without the aid of a microscope. Antonie van Leeuwenhoek described this world when he observed what he called “animalcules” through his simple microscope (**figure 1.1**). What he saw were **microorganisms** (organisms too small to see with the naked eye), including bacteria, protozoa, and some fungi and algae. The microbial world also includes viruses and other infectious agents that are not considered organisms because they are not composed of cells; they are acellular. When referring to general members of the microbial world, the term **microbe** is often used.

Microorganisms are the foundation for all life on Earth. They have existed on this planet for about 3.5 billion years, and over this time, plants, animals, and modern microorganisms have evolved from them. Even today, they continue to be a driving force in the evolution of all living things. Microorganisms may be small, but as you are about to learn, our life depends on their activities.



FIGURE 1.1 Model of van Leeuwenhoek's Microscope The original made in 1673 could magnify an object almost 300 times. The object is brought into focus with the adjusting screws. Tetra Images/Alamy Stock Photo

? What kinds of organisms did van Leeuwenhoek observe through his microscope?

1.1 ■ The Dispute over Spontaneous Generation

Learning Outcomes

1. Describe the key experiments of scientists who disproved spontaneous generation.
2. Explain how the successful challenge to the idea of spontaneous generation led to the Golden Age of Microbiology.
3. Describe the scientific method, using Pasteur's swan-necked flask experiment as an example.

The discovery of microorganisms in various specimens raised an interesting question: "Where did these microscopic forms originate?" Some people believed that worms and other life-forms arise from non-living material in a process known as **spontaneous generation**. This was challenged by an Italian biologist and physician, Francesco Redi. In 1668, he used a simple experiment to show that worms found on rotting meat originated from fly eggs, not from the decaying meat as supporters of spontaneous generation believed. In his experiment, Redi covered the meat with fine gauze that prevented flies from depositing their eggs; when he did this, no worms appeared. Despite Redi's work, it took more than 200 years and many experiments to amass conclusive evidence that microorganisms did not arise by spontaneous generation.

Early Experiments

In 1749, John Needham, a scientist and Catholic priest, showed that flasks containing various broths (made by soaking a nutrient source such as hay or chicken in water) gave rise to microorganisms even when the flasks were boiled and sealed with a

cork. At that time, brief boiling was thought to kill all organisms, so this suggested that microorganisms did indeed arise spontaneously.

In 1776, the animal physiologist and priest Lazzaro Spallanzani obtained results that contradicted Needham's experiments; no bacteria appeared in Spallanzani's broths after boiling. His experiments differed from Needham's in two significant ways: Spallanzani boiled the broths for longer periods, and he sealed the flasks by melting their glass necks closed. Using these techniques, he repeatedly demonstrated that broths remained sterile (free of microorganisms). However, if the neck of the flask cracked, the broth rapidly became cloudy due to the growth of organisms. Spallanzani concluded that microorganisms had entered the broth with the air, and the corks used by Needham and other investigators did not keep them out.

Spallanzani's experiments did not stop the controversy. Some people argued that the heating process destroyed a "vital force" in the air that was necessary for spontaneous generation, and so the debate continued.

Experiments of Pasteur

One giant in science who helped disprove spontaneous generation was Louis Pasteur, the French chemist considered by many to be the father of modern microbiology. In 1861, he did a series of clever experiments. First, he demonstrated that air contains microorganisms. He did this by filtering air through a cotton plug, trapping microorganisms. He then examined the trapped microorganisms with a microscope and found that many looked identical to those described by others who had been studying broths. When Pasteur dropped the cotton plug into a sterilized broth, the broth became cloudy from the growth of these microorganisms.

Most important, Pasteur demonstrated that sterile broths in specially constructed swan-necked flasks remained sterile even when left open to air (**figure 1.2**). Microorganisms from the air settled in the bends of the flask necks, never reaching the broth. Only when the flasks were tipped would microorganisms enter the broth and grow. Pasteur's simple and elegant experiments ended the arguments that unheated air or the broths themselves contained a "vital force" necessary for spontaneous generation. They led to the theory of **biogenesis**, the production of living things from other living things (*bio* means "life"; *genesis* means "to create").

Experiments of Tyndall

Although most scientists were convinced by Pasteur's experiments, some remained skeptical because they could not reproduce his results. An English physicist, John Tyndall, finally explained the conflicting data and, in turn,




FIGURE 1.2 Pasteur's Experiment with the Swan-Necked Flask

? How did this experiment end arguments that a "vital force" in the air was necessary for spontaneous generation?

showed that Pasteur was correct. Tyndall found that various types of broths required different boiling times to be sterilized. Some were sterilized by boiling for 5 minutes, whereas others, most notably broths made from hay, still contained living microorganisms even after boiling for 5 hours! Even when hay was merely present in the laboratory, broths that had previously been sterilized by boiling for 5 minutes could not be sterilized by boiling for several hours. What was going on? Tyndall finally realized that the hay contained heat-resistant forms of microorganisms. When hay was brought into the laboratory, dust particles must have transferred these heat-resistant forms to the broths. Tyndall concluded that some microorganisms exist in two forms: a cell easily killed by boiling, and one that is heat resistant. In the same year (1876), a German botanist, Ferdinand Cohn, discovered **endospores**, the heat-resistant forms of some bacteria.

The extreme heat resistance of endospores explains the differences between Pasteur's results and those of other investigators. Organisms that produce endospores are commonly found in the soil and were likely present in broths made from hay. Pasteur used only broths made with sugar or yeast extract, so his experiments probably did not have endospores. Scientists at the time did not appreciate the importance of the source of the broth, but in hindsight, the source was critical. This points out an important lesson for all scientists: When repeating an experiment, all conditions must be reproduced as closely as possible. What may seem like a trivial difference might be extremely important.

The Golden Age of Microbiology

The work of Pasteur and others in disproving spontaneous generation started an era called the Golden Age of

Microbiology, during which time the field of microbiology blossomed. Many important advances were made during this period, including discoveries that led to the acceptance of the suggestion that microorganisms cause certain diseases, a principle now called the Germ Theory of Disease.

Figure 1.3 lists some of the important advances in microbiology made over the years in the context of other historical events. Rather than cover more history now, we will return to many of these milestones in brief stories called "A Glimpse of History" that open each chapter.

The Scientific Method

The dispute over spontaneous generation offers an excellent example of the process of science. This process, called the **scientific method**, separates science from intuition and beliefs. The scientific method involves a series of steps, including:

- **Making an observation and asking a question about that situation.** An example from this chapter was the observation that microorganisms were present in various examined specimens. This observation led to the question, "Where did the microorganisms originate?"
- **Developing an explanation and then devising an experiment that tests the explanation.** A testable explanation of an observation is called a **hypothesis**, and experiments are done to test the hypothesis. The dispute over spontaneous generation led to two opposing hypotheses: biogenesis and spontaneous generation. Various people designed different experiments to test the hypotheses.
- **Doing the experiment, collecting the data, and drawing a conclusion.** Experiments such as the one illustrated in figure 1.2 provided data about the growth of




FIGURE 1.3 Historical Events in Microbiology Some major milestones in microbiology—and their timeline in relation to other historical events. The gold band indicates the Golden Age of Microbiology.

? What is the Golden Age of Microbiology?

microorganisms in previously sterile broths. In doing a scientific experiment, a critical component is a **control**. A control helps rule out alternative explanations of the results by showing that the only feature that varied in the experiment was the characteristic being tested. Pasteur's swan-necked flask experiment was brilliantly designed because it provided the following control: After showing that the fluid in the swan-necked flasks remained sterile even when opened to air, he tipped the flasks so that bacteria could enter the fluid. By doing this, he showed that nothing in his original set-up would have prevented bacteria from growing in the broth.


- **Communicating the methods, results, and conclusions.** Scientists share their work by publishing it in scientific journals. This step is particularly important because it allows other scientists to repeat the experiment to ensure the validity of the findings. Today, the respected scientific journals use a review process in which other experts in the field read communications before they are published. If deficiencies or flaws are noticed, the reviewers give suggestions for improving the experiments.

When an extensive amount of experimental evidence supports a hypothesis, that explanation may become a scientific **theory**, such as the Germ Theory of Disease. Note that the scientific meaning of the word *theory* is far different from the meaning of the word in common language, which is “a speculation or guess.”

As you read the information in this textbook, continually challenge yourself by asking questions about what you have learned. If you find yourself asking a question such as “How does that happen?” try to develop a hypothesis and then devise an experiment. As you do this, consider the controls you could use. Start learning to think like a scientist!

MicroAssessment 1.1

Experiments of Pasteur and Tyndall helped disprove spontaneous generation by showing that life arises from life. Many important discoveries were made during the Golden Age of Microbiology, including ones that led to the acceptance of the Germ Theory of Disease. The scientific method uses experimental evidence, including proper controls, to support or refute hypotheses.

1. Describe Pasteur's experiment that disproved the idea that a “vital force” in air was responsible for spontaneous generation.
2. How is the meaning of the word “theory” in science different from its meaning in everyday conversation?
3. Why is it important for scientists to repeat the experiments of others? 

1.2 ■ Microbiology: A Human Perspective

Learning Outcomes

4. Explain the importance of microorganisms in the health of humans and the surrounding environment.
5. List three commercial benefits of microorganisms.
6. Describe why microorganisms are useful research tools.
7. Describe the role of microbes in disease, including examples of past triumphs and remaining challenges.

Microorganisms have a tremendous impact on all living things. We could not survive without them, and they also make our lives much more comfortable. At the same time, microbes can be harmful, and they have killed far more people than have ever been killed in war.

The Human Microbiome

Your body carries an enormous population of microorganisms—tens of trillions of bacterial cells alone. Many sources claim that the body carries 10 times as many microbial cells as human cells, but recent and probably more accurate estimates indicate that the ratio is likely closer to 1:1. Regardless, scientists have known for years that these microorganisms, collectively referred to as the **normal microbiota** or normal flora, play an essential role in human health. For example, they prevent disease by competing with disease-causing microbes, help to degrade foods that the body otherwise could not digest, and promote the development of the immune system. In fact, studies indicate that early exposure to certain common microorganisms lessens the likelihood that an individual will develop allergies, asthma, and some other diseases. According to what is sometimes referred to as the “Old Friends” hypothesis, this early exposure helps the immune system learn to distinguish “friendly” microbes from those that can cause severe disease. In addition, animal studies suggest that the composition of the normal microbiota can affect brain chemistry and behavior, as well as the tendency to gain or lose weight.

The important role of the normal microbiota became even more obvious in recent years, thanks in part to the **Human Microbiome Project**. This coordinated set of studies, started in 2007, used DNA sequencing technologies to characterize the microbial communities that inhabit the human body. The term **microbiome** has two overlapping meanings: (1) the total genetic content of a microbial community and (2) the microbial community itself. While the different meanings might seem confusing, they are actually quite similar because at this point the communities must be examined by studying their genetic material. The reason for this is that less than 1% of microorganisms can currently be grown in the laboratory, so for every microbe that had been studied in the laboratory, more than 99 others can only be characterized using DNA sequencing technologies.

The Human Microbiome Project changed the way scientists view the human body and also revealed how much more there is to discover about our microbial partners. To understand their significance, think of Earth's ecosystems (the environments and their interacting inhabitants). Over time, an interacting assortment of organisms has evolved to live in a given environment, resulting in a relatively stable community. Sudden changes can alter individual populations, often with negative consequences to the community as a whole. In turn, a disturbance in one ecosystem can affect the overall health of the planet. The human body, like a planet, is composed of various ecosystems—for example, the desert-like dry areas of the skin, and the nutrient-rich environment of the intestinal tract. An important part of these ecosystems is a population of interacting microbes. Disturbances in a microbial population can create an imbalance that may have negative consequences to that community, which, in turn, can harm a person's health. Observations such as these have led some scientists to suggest that the human body be considered a superorganism, meaning that our own cells interact with the body's normal microbiota to form a single cooperative unit.

The human microbiome's effect on health and disease is an exciting area of active research, but it is more difficult to understand than it might seem. For example, researchers have found that the intestinal microbiome of people diagnosed with depression differs from those who report a good quality of life, but this correlation could be an effect of mood—perhaps even dietary changes associated with certain moods—rather than a cause. Likewise, bacterial species associated with gum disease have been found in the brains of people with Alzheimer's disease, but again, this could be effect rather than cause. Continuing studies aim to clarify the situation.

MicroByte

The Global Microbiome Conservancy is collecting fecal samples from people around the world in an effort to study and preserve the diversity of intestinal bacteria.

Microorganisms in the Environment

Microorganisms are the masters of recycling, and without them we would run out of certain nutrients. For instance, humans and other animals all require nitrogen, an essential part of nucleic acids and proteins. A plentiful source of nitrogen is N_2 —the most common gas in the atmosphere—yet neither plants nor animals can use it. Instead, we depend on certain microbes that convert N_2 into a form of nitrogen that other organisms can use, a process called nitrogen fixation. Without nitrogen-fixing microbes, life as we know it would not exist.

Microorganisms are also important because they can degrade certain materials that other organisms cannot. Cellulose (an important component of plants) is an excellent example. Although humans and other animals cannot digest cellulose, certain microorganisms can, which is why leaves and fallen trees do not pile up in the environment.

Cellulose-degrading microorganisms in the specialized stomach of ruminants (a group of plant-eating animals that includes cattle, sheep, and deer) help those animals digest plant material. Without the assistance of microbes, the ruminants would starve.

In recognition of the important role that microorganisms play in all aspects of life, additional programs promise to expand the scope of existing DNA-based studies. In 2016, the National Microbiome Initiative (NMI) was started to support research on the microbiomes of humans as well as the surrounding environment. Perhaps the most ambitious DNA sequencing program so far is the Earth BioGenome Project, an international effort launched in 2018 to sequence all the known animal, plant, protozoan, and fungal species.

Commercial Benefits of Microorganisms

In addition to the crucial roles microorganisms play in our very existence, they also have made life more comfortable for humans over the centuries.

Food Production

Microorganisms have been used in food production since ancient times. In fact, Egyptians used yeast to make bread and beer. Virtually every population that raised milk-producing animals such as cows and goats also developed procedures to ferment milk. This allowed them to make foods such as yogurt, cheeses, and buttermilk. Today, the bacteria added to some fermented milk products are advertised as probiotics (live microorganisms that provide a health benefit), protecting against digestive disruptions.

Biodegradation

Microorganisms play essential roles in degrading various environmental pollutants. These include materials in wastewater, as well as toxic chemicals in contaminated soil and water. Bacteria also lessen the damage from oil spills. In some cases, microorganisms are added to pollutants to hasten their decay, a process called **bioremediation**.

Commercially Valuable Products from Microorganisms

Microorganisms synthesize a wide variety of commercially valuable products. Examples include: antibiotics used to treat infectious diseases, ethanol used as a biofuel, hydrogen gas and certain oils potentially used as biofuels, amino acids used as dietary supplements, insect toxins used in insecticides, cellulose used in headphones, and polyhydroxybutyrate used in the manufacture of disposable diapers and plastics.

Biotechnology

Biotechnology—the use of microbiological and biochemical techniques to solve practical problems—depends on members of the microbial world. Information learned by studying microorganisms led to easier production of many medications, including the insulin used to treat diabetes. In the past, insulin was isolated from the pancreatic glands of cattle and pigs,

but now certain microorganisms have been genetically engineered to make human insulin. The microbe-produced insulin is easier to obtain, and patients who use it have fewer allergic reactions than occurred with the animal-derived product. Biotechnology also allows scientists to genetically engineer plants to give them desirable qualities.

Microbes as Research Tools

Microorganisms are wonderful model organisms to study because they have the same fundamental metabolic and genetic properties as higher life-forms. All cells are composed of the same chemical elements, and they synthesize their cell structures by similar mechanisms. They all duplicate their DNA, and when they degrade foods to harvest energy, they do so via the same metabolic pathways. To paraphrase a Nobel Prize-winning microbiologist, Dr. Jacques Monod: What is true of elephants is also true of bacteria, and bacteria are much easier to study! In addition, bacteria can be used to obtain results very quickly because they grow rapidly and form billions of cells per milliliter on simple, inexpensive growth media. In fact, most major advances made in the last century toward understanding life have come through the study of microbes.

Microbes and Disease

Although most microbes are beneficial or not harmful, some are **pathogens**, meaning they can cause disease (a noticeable impairment in body function). The disease symptoms can result from damage caused by the pathogen's growth and products or by the body's defense mechanisms inadvertently damaging host tissues during the attempt to control the infection.

To appreciate the effect an infectious disease can have on a population, consider that more Americans died of influenza in 1918–1919 than were killed in World Wars I and II and the Korean, Vietnam, and Iraq wars combined. The COVID-19 pandemic has resulted in the death of more than 1,000,000 people worldwide, including over 200,000 Americans.

Epidemics are not limited to human populations. The great famine in Ireland in the 1800s was due, in part, to a microbial disease of potatoes. A bacterial disease that kills olive trees was found in southern Italy in 2013, and it has since spread to Spain and France, contributing to a recent worldwide drop in olive oil production. A fungal disease called “wheat blast” that devastated wheat crops in South America spread to Bangladesh in 2016, resulting in the loss of over 35,000 acres of crops that year. In 2001, a catastrophic outbreak of foot-and-mouth disease of live-stock occurred in parts of England. To contain this viral disease, one of the most contagious known, almost 4 million pigs, sheep, and cattle were destroyed. More recently, over a million pigs in China either died from African swine fever or were killed to contain the disease, and officials in other countries are trying to limit its spread. Meanwhile, frog populations around the world have been decimated by chytridiomycosis, a fungal disease.




FIGURE 1.4 Trend in Death Rates Due to Infectious Diseases
Crude death rate for infectious disease, United States, per 100,000 population per year.

? Why would the creation of health departments lower the disease rate?

Past Triumphs

The Golden Age of Microbiology included an important period when scientists learned a great deal about pathogens. Between 1876 and 1918, most pathogenic bacteria were identified, and early work on viruses had begun. Once people realized that microbes could cause disease, they tried to prevent their spread. As illustrated in **figure 1.4**, the death rate due to infectious diseases has decreased dramatically over the last 100 years or so, due largely to preventing the spread of pathogens, developing vaccines to provide immunity, and using antibiotics to treat bacterial diseases when they do occur. To maintain this success, we must continue to develop new medications, vaccines, and disease-prevention strategies.

Perhaps the most significant triumph with respect to disease control was the eradication (elimination) of smallpox. This viral disease was one of the most devastating the world has ever known, killing about one-third of those infected. Survivors were sometimes blinded and often left with disfiguring scars. When Europeans carried the disease to the Americas, the effect on the populations of native inhabitants who had not been exposed before was catastrophic. A worldwide vaccination program eliminated the disease in nature, with no cases being reported since 1977. Laboratory stocks of the smallpox virus remain, however, raising the possibility that the virus could be used in bioterrorist attacks.

Polio, a disease that can cause paralysis and sometimes death, was once relatively common, but it has been nearly eliminated because of vaccination. In fact, the disease now occurs in only a few countries, and the goal is to eradicate it globally.

Plague is another major killer that has largely been brought under control. In the fourteenth century, one-third of the population of Europe, or approximately 25 million people, died of this bacterial disease in only 4 years (1347–1351).

We now know that rodents can carry the bacterium, and their fleas can transmit the disease, so we take measures to control the rodent populations. We have also learned that the pneumonic form of the disease (meaning that it is in the lungs) can spread from human to human through respiratory secretions, so special precautions are taken when a patient has pneumonic plague. In addition, the discovery of antibiotics in the twentieth century made treatment possible. As a result, fewer than 100 people worldwide die from plague in a typical year.

Remaining Challenges

Although progress has been impressive against infectious diseases, much more still needs to be done. On a worldwide basis, infectious diseases remain too common, particularly in developing countries. Even in developed countries with sophisticated healthcare systems, infectious diseases remain a serious threat, costing lives and money.

Emerging Infectious Diseases An **emerging infectious disease (EID)** is an infectious disease that has become more common in the last several decades. The EID that everyone is now likely familiar with is COVID-19 (for coronavirus disease 2019), the disease that emerged in late 2019 and then spread rapidly around

the globe. COVID-19 is caused by a virus officially called SARS-CoV-2 (for severe acute respiratory syndrome coronavirus 2) but commonly referred to as the COVID-19 virus. Like COVID-19, many EIDs are new or newly recognized; examples include Ebola disease (EBOD), congenital Zika syndrome, *Candida auris* infection, hepatitis C, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), certain types of influenza, Lyme disease, acquired immunodeficiency syndrome (AIDS), mad cow disease (bovine spongiform encephalopathy), and hantavirus pulmonary syndrome (figure 1.5). Others such as malaria and tuberculosis have been present for years but have spread or become more common recently.

Some diseases arise as infectious agents evolve to infect new hosts, cause different types of damage, or become more difficult to treat because of antibiotic resistance. Genetic analysis indicates that the virus that causes COVID-19 arose from a strain that infects bats. HIV-1 (human immunodeficiency virus type 1), the most common type of HIV to cause AIDS, arose from a virus that infects chimpanzees. A bacterium called *E. coli* O104:H4, which caused a severe food-borne diarrheal outbreak in Europe, appears to have gained the ability to make a specific toxin by acquiring genes from a related organism. Tuberculosis and malaria have increased in




FIGURE 1.5 New and Newly Recognized Infectious Diseases or Disease Agents in Humans and Animals Since 1976 Countries where cases first appeared or were identified appear in a darker shade.

? Why might so many of the diseases first appear or be identified in the United States and Western European countries?

FOCUS ON A CASE 1.1

A 24-year-old woman had suffered from recurrent severe episodes of an intestinal disorder called *Clostridioides* (formerly *Clostridium*) *difficile* infection (CDI) for the past 13 months. She routinely experienced profuse watery diarrhea, abdominal pain, and fever. In addition, she was feeling tired and hopeless because she did not seem to be getting well, despite long attempts at multiple different treatments.

As with most patients who develop CDI, the woman had been taking an oral antibiotic shortly before her symptoms began—in this case, to treat a tooth infection. The antibiotic had successfully killed the bacteria that caused her tooth infection, but it also killed some members of her normal intestinal microbiota. As a result, the bacterium *C. difficile*—often referred to simply as “*C. diff*”—thrive in her intestinal tract, growing to much higher numbers than it could before. The strain that caused her infection was able to make a toxin that damaged the lining of her intestinal tract.

When the patient first started experiencing CDI, her doctor told her to stop taking the antibiotic prescribed for her tooth infection, hoping that her CDI would resolve on its own. When that did not help, the doctor prescribed a different antibiotic that is often effective in treating CDI. The patient started feeling better, but the symptoms quickly

returned when she stopped taking the medication. She also tried oral supplements containing *Lactobacillus* GG, a bacterium that sometimes appears to be effective in preventing antibiotic-associated diarrhea.

Because the patient’s health was declining, doctors suggested a fecal transplant, an experimental procedure that involves inserting feces from a healthy person into the patient’s intestinal tract in order to repopulate that environment with appropriate microbes. They chose to use her sister as a fecal donor, screening both the donor and the patient to ensure that neither was infected with certain microbes, including various intestinal pathogens and HIV. Approximately $\frac{1}{4}$ cup of fresh feces was mixed with 1 quart of water and delivered to her intestinal tract via a colonoscope. Within days after the transplant, the patient began feeling better, and she soon recovered completely.

1. Why would certain oral antibiotics allow *C. difficile* to thrive in the intestinal tract?
2. Why would the doctors screen both the patient and the fecal donor for certain infectious agents?
3. Why would the doctors transplant feces rather than introducing isolated bacteria from feces to repopulate the colon?

Discussion

1. Antibiotics kill or inhibit not just pathogens, but also beneficial members of the normal microbiota, a group that protects against infection in at least two general ways. First, the normal microbiota quickly uses nutrients that would otherwise be available to *C. difficile* and other pathogens. Also, some members of the normal microbiota make compounds that are toxic or inhibitory to other organisms. The environment of the intestinal tract is quite complex, however, so other factors might also be playing a role.
2. Physicians screen the fecal donor to decrease the likelihood that disease-causing microbes could be transferred to the patient by the procedure. The doctors screen the patients to ensure that they are not already infected with the pathogens. For example, if this patient developed symptoms of a *Salmonella* infection after the procedure, how would the physicians know that she acquired the infection as a result of the procedure if they had not checked beforehand?
3. Feces contain many types of bacteria that cannot yet be grown in the laboratory. In addition, scientists do not yet know which types of fecal bacteria protect against CDI.

incidence in recent years, in part because the causative organisms became resistant to many of the available medications.

As the rapid spread of COVID-19 around the globe certainly demonstrated, mobile populations can contribute to disease emergence as people may inadvertently carry pathogens to different regions. Even diseases such as malaria, cholera, plague, and yellow fever that have largely been eliminated from developed countries can be carried to other places if travelers to regions where they still exist become infected and then move on before recovering. Meanwhile, as city suburbs expand into rural areas, human populations come into closer contact with animals as well as the mosquitoes and other arthropods that normally feed on those animals. Consequently, people are exposed to pathogens they might not have encountered previously.

The preventive measures used to control certain infectious diseases can become victims of their own success, a situation that can also lead to disease emergence. Decades of vaccination have nearly eliminated measles, mumps, and whooping cough in developed countries, so most people no longer have firsthand knowledge of the dangers of these diseases. Couple this

with misinformation about vaccines, and some people develop irrational fears, falsely believing that vaccines are more harmful than the diseases they prevent. When this happens, parents often refuse to vaccinate their children appropriately, leading to situations where the diseases become more common again. Measles had been declared eliminated in the United States in 2000, but outbreaks in 2019 resulted in the highest number of cases in 25 years. Outbreaks generally start with unvaccinated travelers who bring the disease into the country, where it then spreads among others who are not vaccinated.

Chronic Diseases Some chronic illnesses once attributed to other causes may be due to microorganisms. Perhaps the best-known example is stomach ulcers, once thought to be due to stress. We now know that stomach ulcers are often caused by a bacterium (*Helicobacter pylori*) and are treatable with antibiotics. Chronic indigestion may be caused by the same bacterium. Another example is cervical cancer, which we now know is caused by human papillomavirus (HPV) infection; a vaccine against HPV prevents that cancer. Infectious microbes may play important roles in other chronic diseases as well.